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Breast cancer is the most common cancer in females around the world. 
Annually, more than one million women are diagnosed with breast cancer 
globally. In Oman, breast cancer is also the most common cancer in females and 
its incidence has been rising over the years. Published studies have shown that 
many Omani women have late stage breast cancer at presentation. Possible 
reasons for this have not been explored. Although Oman has in place a mortality 
registration database, no population-based mortality data from breast cancer are 
available. Likewise, the only data available about survival rate of people with 
breast cancer come from a hospital-based study.  
Aims 
The main aims of the research described in this thesis are: 
1) To identify the extent of delay in breast cancer diagnosis in Oman. 
2) To assess the relationship between delay and socio-demographic 
characteristics, medical and obstetric history, nature of presenting 
symptoms and women’s knowledge about breast cancer. 
3) To identify reasons for delay in seeking medical help for self-detected 
breast cancer symptoms in Omani women. 
4) To calculate the population-based survival rate from breast cancer in 
Oman. 
Methods 
Aims 1, 2 and 3 were addressed by a study of 150 patients attending oncology 
clinics in both the Royal Hospital and Sultan Qaboos University Hospital, who 
were interviewed using structured questionnaires. Patient delay was defined as a 
period of three months or more between an individual's first awareness of a sign 
or a symptom of illness and the initial medical consultation. 
In order to calculate survival rate, the National Cancer Registry records were to 
be linked to mortality databases in Oman (Directorate General of Civil Status 
and to the Parallel Mortality Database).    
 iii 
Results  
The final analysis of delay included 144 patients with breast cancer. The median 
time taken by women in this sample between discovering the breast symptoms 
and seeing a doctor was 14 days. 56.9% of the patients had a medical 
consultation in less than a month after detecting symptoms, whereas 20.1 % had 
a consultation within 1 to 2 months. 22.9 % of the patients delayed consultation 
by ≥ 3 months. Of the socio-demographic characteristics examined in this study, 
it was observed that older age, low educational level and employment status 
were associated with patient delay. Practice of breast self-examination and 
having a history of chronic disease were also predictors of delay. 44% of 
patients had early stage disease (stage I/stage II) compared to 56% of patients 
with late stage disease (stage III/stage IV). However, patient delay was not 
associated with advanced stage cancer in this study.  
The main reasons given for delay were: failure to recognise the symptoms to be 
breast cancer, not seeing oneself at risk for breast cancer, fear and 
embarrassment, use of alternative therapy and family and work commitments.  
Due to ethical consideration, I was not able obtain data from Omani NCR and 
therefore the linking to mortality databases was not possible.   
Conclusion 
This study is the first in Oman to investigate the extent of patient delay for 
women with self-discovered breast symptoms and the factors that influence this 
delay. The findings of this study indicate the need for public education aimed at 
raising breast cancer awareness. Further, initiating a screening program in 
Oman should be considered to help women achieve diagnosis of the disease in 
its early stages.  
Population-based cancer research should be encouraged in Oman, and efforts 
should be taken to improve the quality and completeness of cancer data, which 
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1.  Chapter One - Introduction and Background 
1.1 Introduction  
Breast cancer is the most common cancer among women. In 2008, there were 
around 1.38 million new female breast cancer cases diagnosed worldwide 
(Ferley et al., 2010). The incidence rate was almost two and a half times higher 
in more developed countries compared to less developed countries (Ferley et al., 
2010). This is mainly as a result of a higher prevalence of the known risk factors 
for the disease in developed countries relative to less developed countries, and 
lack of awareness and organised screening programs in developing countries 
(Coughlin and Ekwueme, 2009, Ferlay et al., 2010). Breast cancer is the most 
common cause of cancer death in women worldwide, estimated to be 
responsible for around 458,500 female deaths in 2008 or nearly one in seven 
(around 14%) of all cancer deaths in women (Ferley et al., 2010).  
In the Gulf Cooperation Council Countries (GCC), breast cancer is the most 
common malignancy among women with the incidence being higher in Bahrain, 
Kuwait and Qatar and lower in Oman, United Arab Emirates and Saudi Arabia 
(Al-Madouj et al., 2011). The incidence of breast cancer in the GCC countries 
starts to increase among women in their mid-20s and steeply increases for 
women in their late 40s then there is a slow increase in the rest of their lives. In 
2011, the age standardized incidence rate (ASR) was 25.5 per 100,000 women 
accounting for 24.8% of all female cancer in Oman (Al Lawati et al., 2013).  
Oman is a high-income developing country. It has a population of 2,137,807 
Omani, and shows a gender ratio of 983 females per 1000 males. About 13.2% 
of the population is under 5 years, 34% is under 15 years and 3.8% of the total 
Omani population is above the age of 60 years (Al Lawati et al., 2013). Health 
care is free for all Omanis (Nooyi and Al-Lawati, 2011). The standards of health 
services in Oman have been brought up to those of industrialized nations and 
health services include treatments such as organ transplants and open-heart 
surgery.  The establishment of the National Oncology Centre in the Royal 
Hospital in the capital, Muscat, has enabled the availability of comprehensive 
cancer care in Oman (Nooyi and Al-Lawati, 2011). However, findings indicate 
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that the majority of Omani women are being diagnosed at late stages of the 
disease (stage III and IV) (Al-Moundhri et al., 2004, Al-Moundhri et al., 2011, 
Al-Moundhri et al., 2003). It is well documented that prognosis of breast cancer 
depends on the stage at diagnosis and those diagnosed at an earlier stage show 
better survival rate (Kumar et al., 2007). Moreover, advanced stages of the 
disease are shown to be a result of longer delays in seeking diagnosis for breast 
symptoms and those who presented earlier usually have smaller tumours with 
more favourable outcomes (Unger-Saldaña and Infante-Castañeda, 2009). Early 
care seeking is a principle in oncology, and delay in diagnosis and treatment of 
cancer has been the subject of research for decades. As early as 1938, Pack and 
Gallo defined the term patient delay as ‘the time elapsing between first 
symptom and first visit with a physician’ (Pack and Gallo, 1938). The reasons 
for delayed care seeking among cancer patients have been thoroughly explored 
but not in Oman.  
This study addresses the issue of patient delay among Omani women by 
assessing the magnitude of delay and also evaluates possible factors causing 
delay. Because early diagnosis of breast cancer is important for improving 
quality of life and survival rate, breast cancer screening is the best mode of 
obtaining this goal. Hopefully, this study may help to inform decision-making 
about whether a screening program should be implemented to downstage breast 
cancer cases in Oman.  
Policies and programmes to address health problems in a population require an 
understanding of the nature and extent of the problems, their causes and changes 
over time (Mathers et al., 2005). Various statistics need to be provided: the 
incidence of the disease, prevalence in the population, mortality and survival 
rates. While incidence data on breast cancer in Oman is available (Al Lawati et 
al., 2013), information regarding mortality is still lacking. Likewise, survival 
data available on breast cancer come only from hospital based studies. In 2004, 
a vital registration system, the Directorate General of Civil Status (DGCS), was 
established where population-based deaths are recorded. Despite the 
establishment of the DGCS, no data on population-based mortality or survival 
from breast cancer were available. Therefore, as a result of this study, I am 
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hoping to close this gap and provide at least estimates of mortality and survival 
from breast cancer in Oman. 
1.2 Overview of the thesis 
The organization of the chapters is as follows: 
• Chapter 1 provides an overview of the thesis and a background 
regarding descriptive epidemiology, the clinical features, and pathology 
of breast cancer. 
• Chapter 2 will examine the available literature that addresses the 
epidemiology of breast cancer in GCC countries, risk factors in the Arab 
populations and the problem of delay in seeking medical help for self-
discovered breast symptoms.  
• Chapter 3 will describe the study conducted to examine patient delay 
among Omani women with breast cancer to measure the magnitude of 
delay and identify factors associated with delay.  
• Chapter 4 will describe the attempt to calculate survival rate of breast 
cancer in Oman beside discussing the importance of actively collecting 
data on mortality and survival rates and their application to breast cancer 
in Oman.  
• Chapter 5 provides the main findings and implications of this study. 
1.3 Search strategy for the background and literature review 
• Database used: The following databases were used to search for relevant 
articles and keywords on the topic: Ovid via the Medline database, 
PubMed, and Scopus. Reading started with the most recent review 
articles, and then sought out the important referenced sources. 
References from relevant studies were also used to trace other studies. 
Additionally, four websites were also valuable for the search, which 
were the World Health Organization Statistical Information System 
database (http://www.who.int/whosis/en/), the International Agency for 
Research on Cancer (IARC) (www.iarc.fr/), American Cancer Society 
(www.cancer.org/) and finally, Oman Ministry of Health 
(www.moh.gov.om/)    
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• References and keywords: The initial list of keywords used to identify 
relevant articles included: “epidemiology”, “breast”, “cancer”, 
“incidence”, “mortality”, “survival”, “survival analysis”, “ethnicity”, 
“aetiology”, “cause”, “risk factors”, “prognosis”, “pathology”, 
“histology”, “histopathology”, “treatment”, “therapy”, “clinical 
features”, “signs”, “symptoms”, “prevention”, “screening”, “Arab”, 
“Oman”, “delay”, “patient’s delay”, “late diagnosis”, “diagnosis delay”, 
“help seeking behaviour”, “late stage” “developing countries” and 
“Middle East”. 
1.4 Background  
This section will provide an overview of breast diseases followed by general 
information regarding the clinical aspects of breast cancer including signs and 
symptoms, diagnosis, treatment and prognosis. An overview of global breast 
cancer epidemiology is also provided.  
1.4.1 Pathology of the breast  
Breast	  diseases	  
Breast cancer is the most common malignancy among females (Ferley et al., 
2010). Nevertheless, benign lesions of the breast are far more frequent than 
malignant tumours. Benign breast disease includes a heterogeneous group of 
lesions that may express a wide range of symptoms (Guray and Sahin, 2006). 
Benign breast lesions usually have a high incidence during the second decade of 
life and peak in the fourth and fifth decades (Guray and Sahin, 2006). The 
World Health Organisation stated that among 100 female patients aged 40-65 
years presenting with breast complaints, the following is likely: 30% have no 
breast lesion, 40% have fibrocystic changes, 7% have a benign tumour 
diagnosis and 10% have carcinoma (Khatib and Modjtabai, 2006).  
Acute and chronic inflammatory lesions of the breast like acute mastitis, duct 
ectasia, post-traumatic lesions and granulomatous mastitis together with non-
proliferative cystic lesions are benign breast diseases that are not associated 
with increased risk for breast cancer (Fan and Thomas, 2011).  On the other 
hand, fibrocystic proliferative changes such as lobular/ductal hyperplasia with 
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or without atypia and adenosis belong to the group of benign diseases, which 
are associated with increased risk of developing breast carcinoma (Thomas, 
2011).   
Tumours are the most important lesions of the breast. Fibroadenoma is by far 
the most common benign neoplasm of the female breast (Lioe and Cameron, 
2013). Other tumours such as phyllodes tumours and intraductal papilloma are 
less frequent and though most of time they remain benign, progression to 
malignant lesions may occur. 
Carcinoma is by far the most common malignant neoplasm of the breast. It 
affects the left breast slightly more often than the right. About 4% of women 
with breast cancer have bilateral primary tumours or sequential lesions in the 
same breast. 50% of tumours occur within the upper outer quadrant of the 
breast. The remaining quadrants are each involved into about 10%, and the 
subareolar area is the initial site of presentation in 20% of tumours. Breast 
cancer can be divided into two main groups: non-invasive or carcinoma in situ, 
and invasive carcinoma. Table 1-1 presents the incidence of various breast 









Note:	  data	  adapted	  from	  (Khatib and Modjtabai, 2006) 
 
Table 1-1: Incidence of various types of breast malignant tumours 
Type Incidence 
In situ carcinoma 15-30% 
Ductal carcinoma in situ 80% 
Lobular carcinoma in situ 20% 
Invasive carcinoma 70-85% 
Ductal carcinoma (no special type) 79% 
Lobular carcinoma 10% 
Tubular/ cribriform carcinoma 6% 
Mucinous carcinoma 2% 
Medullary carcinoma 2% 
Papillary carcinoma 1% 
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1.4.2 Clinical aspects of breast cancer 
Breast	  cancer	  signs	  and	  symptoms	  
The American Cancer Society highlighted signs and symptoms of breast cancer 
in its publication Breast Cancer Facts and Figures: 2009-2010 (2010). It states 
that breast cancer usually produces no symptoms when the tumour is small and 
most treatable. A lump is by far the most common presentation.  Most of the 
time it is painless, shows irregular borders, is firm and appears fixed to the 
underlying tissues or to the overlying skin. Pain is not usually present in breast 
cancer; only 5 % of patients with malignant mass present with breast pain. 
Another uncommon and alarming symptom is nipple discharge particularly 
when the discharge is blood stained. Other nipple abnormalities may indicate 
breast cancer such as erosion, inversion and tenderness.  Less common signs 
and symptoms include heaviness and persistent changes to the breast such as 
swelling, thickening or redness of the skin of the breast. In some cases breast 
cancer may spread to the axillary lymph nodes and cause a lump or swelling, 
even before the original breast tumour is felt.  
Diagnosis	  of	  breast	  cancer	  
It is recommended that any abnormal lesion, which is detected by the woman 
herself or through breast screening, to be evaluated using the ‘triple assessment’ 
approach (Lioe and Cameron, 2013). Triple assessment has an overall accuracy 
of 99.3% in evaluating patients with breast lumps and detecting patients with 
breast cancers (Jan et al., 2010). Lioe and Cameron (2013) described the process 
of this assessment, which usually starts with a clinical examination where 
symptomatic patients are referred to designated breast clinics, and assessed by 
multidisciplinary teams. Then radiological imaging is performed where a 
diagnostic mammography is used to determine size and location of the 
abnormalities in older women. Otherwise, ultrasonography is indicated for 
younger women.  Sometimes the ipsilateral axilla is scanned using ultrasound to 
assess any enlarged or abnormal lymph nodes. Finally, any detected 
abnormality or suspicious areas of microcalcifications are further investigated 
using aspiration and/or biopsy. Clinicians may perform fine needle biopsy to 
characterize the cellular components of cystic lesions or use core needle biopsy 
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to investigate non-nodular or non-palpable lesions detected as mammographic 
microcalcifications.  
Histological assessment of the tissue is then carried out to characterize the 
tumour based on microscopic organisation and growth pattern of cancer cells 
(Bateman, 2006). Tumour marker assay is now widely used to determine 
subtypes of breast cancer along with immuno-histochemistry of oestrogen and 
progesterone receptor status. Histopathological parameters are also used to 
determine tumour stage to achieve a prognosis.  
Stage	  
The staging of breast tumours provides a description of the extent and spread of 
a tumour (Phipps and Li, 2010). The most common system used to describe the 
stages of breast cancer is the American Joint Committee on Cancer (AJCC) 
TNM system (Compton et al., 2012). Specifically, tumour stage is determined 
by the size of the tumour, number of involved lymph nodes, and whether the 
cancer has spread to other parts of the body.  
The TNM staging system classifies cancers based on their T, N, and M stages: 
• The letter T followed by a number from 0 to 4 describes the tumour’s 
size and spread to the skin or to the chest wall under the breast. Higher T 
numbers mean a larger tumour and/or wider spread to tissues near the 
breast. 
• The letter N followed by a number from 0 to 3 indicates whether the 
cancer has spread to lymph nodes near the breast and, if so, how many 
lymph nodes are affected. 
• The letter M followed by a 0 or 1 indicates whether the cancer has 
spread to distant organs for example, the lungs or bones. 
Once the T, N, and M categories have been determined, this information is 
combined in a process called stage grouping (Table 1-2). Cancers with similar 
stages tend to have a similar outlook and are often treated in a similar way. The 
stage is expressed in Roman numerals from stage 0 to stage IV.  Stage 0 breast 
cancer (i.e., in situ breast cancer) is characterized by an accumulation of 
malignant cells that have not invaded into surrounding tissue. Breast tumours 
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designated as stage I, II, III, or IV involve some invasion of tumour cells 
beyond the basement membrane, and are thus referred to as invasive tumours. 
Stage I breast cancer is confined to the breast tissue and has a maximum 
diameter of less than 2 cm while stage IV breast cancer involves distant 
metastases.  
Table 1-2: TNM stage grouping of breast cancer 
Stage T N M 
Stage 0 Tis N0 M0 
Stage IA T1 N0 M0 
Stage IB T0 N1mi M0 
 T1 N1mi M0 
Stage IIA T0 N1 M0 
 T1 N1 M0 
 T2 N0 M0 
Stage IIB T2 N1 M0 
 T3 N0 M0 
Stage IIIA T0 N2 M0 
 T1 N2 M0 
 T2 N2 M0 
 T3 N1 M0 
 T3 N2 M0 
Stage IIIB T4 N0 M0 
 T4 N1 M0 
 T4 N2 M0 
Stage IIIC Any T N3 M0 
Stage IV Any T Any N M1 
Note:	  data	  adapted	  from	  (Compton et al., 2012) 
Grade	  	  
Tumour grade provides a description of how closely breast tumour cells 
resemble normal breast tissue when viewed microscopically (Phipps and Li, 
2010). In situ ductal carcinoma and all invasive tumours are routinely graded. 
The grade is defined according to three morphologic features of breast tumour 
cells: (1) the degree of tumour tubule formation, (2) mitotic activity, and (3) 
nuclear pleomorphism (Fabbri et al., 2008). The three values are added together 
to produces scores of 3 to 9, to which the grade is assigned: 
• Point total 5: grade 1, well differentiated; 
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• Point total 6–7: grade 2, moderately differentiated; 
• Point total 8–9: grade 3, poorly differentiated 
Thus, across grading scales, a lower grade is indicative of slower growing 
cancer that is less likely to spread and a higher grade is indicative of more 
aggressive, rapidly progressive disease. The grade is an important predictor of 
both disease free and overall survival (Phipps and Li, 2010). 
Treatment	  
Surgery is considered the primary treatment for primary breast cancer. Many 
patients are cured with surgery; otherwise, adjuvant treatment involving 
radiation and systemic therapy (including chemotherapeutic, hormonal, and 
biologic agents) might be undertaken to treat micrometastatic disease.  
Jatoi (2010) outlines in Management of Breast Diseases the surgical options for 
patients with breast cancer. Breast conserving surgery is an option for patients 
with lateral breast cancer showing small and localised tumours. Usually the 
surgery is followed by radiotherapy to eliminate occult tumour foci remaining in 
the ipsilateral breast (Sainsbury et al., 2000). Larger tumours require a modified 
radical mastectomy (MT) in which the entire breast tissue and the ipsilateral 
lymph nodes are removed leaving the muscle of the chest intact. It is 
recommended that patients choosing this treatment must undergo 
postmastectomy radiation if the primary tumour is > 5cm, and involves ≥ 4 
lymph nodes (Recht et al., 2001). Additionally, some women with unilateral 
breast cancer might be treated with a modified radical MT and a contralateral 
prophylactic MT (i.e., bilateral MT), particularly if they carry the BRCA 1 or 
BRCA 2 gene mutations or have anxiety over the possibility of developing a 
new cancer in the opposite breast.  
Chemotherapy is the initial therapy for ER-negative/Progesterone Receptor-
negative metastatic breast cancer, or metastatic breast cancer with widespread, 
symptomatic visceral disease (Kurian and Carlson, 2010). The type and duration 
of chemotherapeutic agents should be adjusted according to patient tolerance to 
avoid cumulative toxicity.  
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Finally, postoperative mammography should be performed as a follow-up for all 
patients who have had surgery (Mariani and Gianni, 2008) (Sainsbury et al., 
2000). The first mammogram is best-performed six months postoperatively to 
provide a baseline for the new postoperative and post-irradiation changes. 
Thereafter, mammography may be performed every 6-12 months for screening 
and follow-up. Monitoring of any metastatic disease is also recommended for 
high-risk patients, which should include monthly evaluations consisting of a 
history, and physical examination to evaluate any progression of disease. 
Prognosis	  	  
As the range of options for treatment of breast cancer widens, so it becomes 
increasingly important that the clinician is provided with accurate prognostic 
information on which to base therapeutic decisions. Prognostic factors are 
tumour characteristics that are associated with the risk of breast cancer 
recurrence and death. Many prognostic factors have been identified over the 
years.  
A brief outline of common prognostic factors as stated in Robbins Basic 
Pathology (Kumar et al., 2007). The TNM staging of the tumour is important. 
Ten-year survival estimates in the US according to breast cancer stage are 
presented in Figure 1-1.  Patients with small invasive carcinomas and no distant 
metastases have a better prognosis. Similarly, nodal involvement is a significant 
prognostic factor where absence of axillary node involvement shows a 5-year 
survival rate close to 90%.  The survival rate decreases with each involved node 
and is less than 50% with 16 or more involved nodes.  
 
Figure 1-1: Ten-year relative survival associated with AJCC/UICC (TNM) breast cancer stages 
Note:	  Figure	  adapted	  from	  (Singletary and Connolly, 2006)) 
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A number of other tumour pathologic factors are used to further refine estimates 
of breast cancer prognosis, including tumour grade, tumour histology, level of 
steroid hormone receptor expression, and amplification or overexpression of the 
HER-2/NEU oncogene. Well-differentiated tumours have a significantly better 
prognosis compared to poorly differentiated tumours. Moderately differentiated 
carcinomas have a better prognosis initially, but survival at 20 years approaches 
that of poorly differentiated carcinomas.  
Approximately 80% of breast cancers in developed countries are of ductal 
histology with approximately 10–15% of tumours being of lobular histology 
(Li, 2010). The less common tubular and mucinous histological types usually 
grow slowly and therefore have a more favourable prognosis (Li, 2010). The 
presence of hormone receptors offer a better prognosis where higher levels of 
expression of receptors for oestrogen and progesterone associate with improved 
survival. The reason is that tumours with oestrogen and progesterone receptors 
show high rates of response (80%) to anti-oestrogen therapy. In contrast, 
tumours with only one receptor present show lower rates of response (25%-
45%) and only 10% response if both receptors are absent (Kumar et al., 2007). 
Amplification or over-expression of the HER-2/NEU oncogene correlates with 
early recurrence and worse outcomes. Age is a prognostic factor, in part, 
because breast cancers diagnosed before menopause often have unfavourable 
pathologic features, and young patients, therefore, have shorter survival (Kumar 
et al., 2007). 
1.4.3 Descriptive epidemiology of breast cancer 
By	  person	   	  	  
Breast cancer exhibits gender differences. Though most cancer types occur 
more among males compared to females, male breast cancer is rare, accounting 
for an incidence of less than 1 per 100,000 man-years (Ly et al., 2013). Male 
breast cancer makes up less than 1% of all cancers in men (Miao et al., 2011). In 
the other hand, breast cancer is by far the most frequent cancer among females. 
In 2008 breast cancer represented 23% of all invasive cancer diagnosed amongst 
females (Ferley et al., 2010). The female-to-male incidence ratio for breast 
cancer for the period 1988-2002 is calculated to be 122 (Ly et al., 2013). Due to 
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lack of awareness of its occurrence among men and lack of an early detection 
programme for men, male breast cancer is usually diagnosed at a more 
advanced stage and with a more severe clinical presentation than in women (Ly 
et al., 2013) (Miao et al., 2011). Because breast cancer in males is less common 
and because the main interest of this research is female breast cancer, the rest of 
the background concentrates only on breast cancer in women.  
Age is considered to be the greatest risk for developing breast cancer 
(Kamangar et al., 2006). While the incidence of most epithelial cancers 
increases steadily with aging, breast cancer has a unique age-specific curve 
(Figure 1-2) (Kamangar et al., 2006, Bray et al., 2004). Before menopause (age 
40-50 years), there is a rapid increase in incidence rate of breast cancer; then 
after that, and due to low levels of circulating oestrogens, the rise in incidence is 
slow (Bray et al., 2004, Ferlay et al., 2010). The midlife inflection in the age-
specific curve is termed ‘Clemmesen’s hook’ and has been attributed to 
menopause (Kamangar et al., 2006). It is noted that the slope of the curve after 
menopause varies worldwide. While it continues to rise more slowly in more 
developed (high risk) countries, it flattens or falls in less developed (low risk) 
countries (Bray et al., 2004). Some investigators attribute this to increased risk 
of occurrence in consecutive generations of women rather than a real decline in 
risk with age (Kamangar et al., 2006, Ferlay et al., 2010). Others link it with the 
existence of two types of breast cancer according to oestrogen receptors (ER) 
expression (Anderson et al., 2002, Kamangar et al., 2006). ER-positive tumours 
are more common in carcinomas occurring in more developed countries such as 
lobular and tubular carcinomas. The rate of ER-positive tumours rises rapidly 
until the age of 50 years and then slowly decreases after that, consistent with the 
age-specific curve observed in more developed countries. In contrast, ER-
negative tumours are most common in medullary breast carcinomas, which are 
rare tumours occurring in women in less developed regions. The ER-negative 
tumour incidence rate follows that of less developed countries in which it rises 
rapidly till menopause and then reaches a plateau (Kamangar et al., 2006).  
The mean age of diagnosis of breast cancer in less developed countries is 
younger than in more developed countries due to the young age structure of 
population coupled with a flatter postmenopausal age-incidence curve in less 
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developed countries (Ferlay et al., 2010, Bray et al., 2004). Worldwide, 89% of 
breast cancers are diagnosed from the age of 40 onwards (Ferley et al., 2010) 
but there is a difference between more developed countries (95%) and less 
developed countries (85%) (Youlden et al., 2012). 
Breast cancer is characterized by marked differences in the incidence rate by 
ethnicity. For example, breast cancer incidence in the United States (US) was 
highest among white women followed by African Americans, Asian 
American/Pacific Islanders, Hispanics/Latinas, and American Indians/ Alaska 
Natives (Smigal et al., 2006). Research shows that while the incidence is highest 
among white women, they are more likely to be diagnosed with localized 
tumours compared to groups with lower incidence where they are diagnosed at 
regional/distant stages. This difference is also noted in South Africa where 
Stages III and IV of breast cancer were more common in black women 
compared with the nonblack women (Vorobiof et al., 2001).  
Another finding for ethnic differences comes from New Zealand, with Māori 
women having the highest rates followed by Pakeha, and Pacific and Asian 
women, who experience the lowest rates (Ellison-Loschmann et al., 2013).  
 
Figure 1-2: Age-specific breast cancer incidence in developed (white circles) and developing 
countries (black circles). 
Note:	  Figure	  adapted	  from (Kamangar et al., 2006) 
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  By	  place	  
In 2008, there were around 1.38 million new female breast cancer cases 
diagnosed worldwide (Ferley et al., 2010).  Incidence rate was almost two and a 
half times higher in more developed countries compared to less developed 
countries (66.4/ 100,000 and 27.3/100,000, respectively) (Ferley et al., 2010). 
Female breast cancer incidence rates varied internationally by more than 13-fold 
in 2008, ranging from 8.0 cases per 100,000 in Mongolia and Bhutan to 109.4 
per 100,000 in Belgium (Figure 1-3). In general, the highest rates are observed 
in Western and Northern Europe, Australia/New Zealand and North America; 
intermediate rates in South America, Caribbean, and Northern Africa; and low 
rates in sub-Saharan Africa and Asia (Bray et al., 2004, Ferlay et al., 2010). 
The large variation in breast cancer incidence rates between less developed and 
more developed countries reflects differences in risk factors. In general, the high 
incidence rates of breast cancer in more developed countries are the result of a 
higher prevalence of the known risk factors for the disease relative to less 
developed countries (Ferlay et al., 2010, Jemal et al., 2011). Women in 
developed countries, for example, tend to have fewer children, give birth at an 
older age and are less likely to breastfeed. In addition, obesity, alcohol 
consumption and exposure to exogenous hormones (example, oral contraceptive 
and hormonal replacement therapy) may also contribute to the higher rates. 
Over diagnosis of some cancer cases in developed countries as a consequence of 
organised screening programmes might also add to the rise in cases compared to 
less developed countries where some cases remain undetected due to lack of 
diagnostic and health care facilities (Youlden et al., 2012). 
Incidence by stage also exhibits a geographical variation. In less developed 
countries breast cancer tends to be diagnosed at a late stage compared with more 
developed countries where cases are diagnosed much earlier. For example, in 
the US and Australia, 60% of cases diagnosed were localised in contrast to 25% 
of cases diagnosed in less developed countries (Youlden et al., 2012). Lack of 
public awareness and organised screening programs in less developed countries 
may explain the variation in stage observed between countries (Coughlin and 
Ekwueme, 2009, Agarwal et al., 2009).  It is also important to acknowledge that 
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the availability and quality of primary health care might also contribute to the 
difference noticed. In less developed countries even if the women present early, 
they may still be faced with delay or inadequate treatment (Agarwal et al., 2009, 
Coughlin and Ekwueme, 2009). 
 
Figure 1-3: Age standardized breast cancer incidence and mortality rates by world area 
*Estimated age-standardized rates (World) per 100,000. Note:	  Figure	  from GLOBOCAN 2008 (Ferley et 
al., 2010) 
By	  time	  
Breast cancer incidence rate has increased worldwide over the past several 
decades. The largest increase in incidence occurs in populations with 
historically low-incidence rate, often in developing countries whereas relatively 
recent decrease in incidence rates have been observed in several, mainly 
western countries (Ferlay et al., 2010). The incidence rate of breast cancer 
increased by 30% in westernised countries between 1980 and the 1990s (Althuis 
et al., 2005). 
Figure 1-4 demonstrates trends in breast cancer incidence observed in some 
developed countries from 1965 to 2005. In countries of Northern America 
including US and Canada, there was a rise in incidence between 1980s and 
1987, which was related to increase in mammography-detected incident cases 
(Bray et al., 2004). In the US, the incidence rate of breast cancer decreased 
between 1999 and 2003 and research suggests it might be due to saturation in 
screening programs and/or due to decreased use of postmenopausal combined 
hormonal therapy (Ferlay et al., 2010). The incidence rates increased 
substantially across various European countries through the mid-1990s (Ferlay 
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et al., 2010, Bray et al., 2004). A mean global increase of 56.5% was observed 
between 1990 and 2002 across all age groups, and the greatest increase was 
observed across central and eastern European countries (Héry et al., 2008).  
  
Figure 1-4: Age standardized incidence rate of breast cancer in selected developed countries 
Note:	  Figure	  adopted	  from	  (Ferlay et al., 2010) 
Figure 1-5 shows breast cancer incidence in some developing countries between 
1968 and 1998. Developing countries have low to moderate rates of breast 
cancer incidence compared with that in developed countries (Ferlay et al., 
2010). Breast cancer incidence rates have been rising in these countries. 
Between 1983-1987 there was a 40% increase in the rate of breast cancer in 
India (Bray et al., 2004). In Singapore there was a threefold increase in the rate 
between 1968 and 2002 (Ferlay et al., 2010). Countries of Africa including 
Uganda, Nigeria experienced a twofold increase between 1960s and the late 
1990s (Parkin et al., 2003). Similar trends were observed in the countries of 
Latin America (Bray et al., 2004).   
 
Figure 1-5: Age standardized incidence rate of breast cancer in selected developing countries 
Note:	  Figure	  adopted	  from	  (Ferlay	  et	  al.,	  2010) 
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The rising rates of breast cancer observed in developing countries might be 
attributed to the “westernization” of lifestyles, in particular to delayed 
childbearing, lower parity, lower breastfeeding duration, consumption of 
calorie-dense food, physical inactivity and obesity (Bray et al., 2004, Jemal et 
al., 2011)  
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2 Chapter Two - Literature Review 
This chapter examines the available literature on breast cancer related to this 
thesis. There will be an outline of the epidemiology of breast cancer in Gulf 
countries and then in Oman followed by an overview of risk factors for breast 
cancer among Arab women. Then, a summary of women’s perception of breast 
cancer and perceived personal risk will be provided as they are important 
concepts that influence women’s decisions regarding health behaviour and 
involvement in prevention programs. Finally, literature on patient delay and 
breast cancer will be summarised to identify the most common factors which 
influence women to delay seeking medical help.   
2.1 Epidemiology of breast cancer in Gulf Cooperation Council 
Countries 
Countries of the Gulf Cooperation Council (GCC) share similarities in culture, 
lifestyle, and environment, and hence it is believed they share similar health 
risks (Chouchane et al., 2013). Nonetheless, cancer incidence and prevalence 
are reported at differing levels among populations of the GCC countries (Al-
Hamdan et al., 2009). Incidence data in GCC countries reported in this section 
of the thesis are obtained from the report 10-Year Cancer Incidence Among 
Nationals of the GCC States, 1998-2007 published by the Gulf Centre for 
Cancer Registration (GCCR) (Al-Madouj et al., 2011). The GCCR was 
established in 1998 to create a population-based incidence database for the GCC 
countries which includes United Arab Emirates (UAE), Kingdom of Bahrain, 
Kingdom of Saudi Arabia (KSA), Sultanate of Oman, State of Qatar, and State 
of Kuwait (Al-Madouj et al., 2011) . The NCR in each country is responsible for 
data collection at the national level from health facilities. Most of the national 
cancer registries in the Gulf countries were established in the 1990s (Al-
Mahrouqi et al., 2011) except for Kuwait which was started in 1971 (Curado et 
al., 2008). To ensure comprehensive data collection, a ministerial decree in each 
of the GCC countries has rendered cancer a reportable disease by all Ministry of 
Health hospitals, and government and private hospitals, clinics and laboratories 
(Al-Hamdan et al., 2009). Mandatory reporting started in 1998 or earlier in 
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Kuwait, Bahrain, Saudi Arabia and Qatar and was only around the beginning of 
2001 that it started in Oman and UAE (Al-Mahrouqi et al., 2011). Data on 
cancer site, histology, stage, behaviour and extent of the disease, basis of 
diagnosis and methods of treatment are collected from patients’ medical 
records, histopathology and radiology reports, clinical notes, and death 
certificates at National Cancer Registries (NCRs) in each member state. Data 
are sent to the GCCR in different formats (e.g. Excel, Epi-Info) and at the 
GCCR all files are converted to CanReg format, validated software for 
processing cancer data developed by the International Agency for Research on 
Cancer (IARC), and subsequently analysed (Al-Hamdan et al., 2009).  
Between 1998 and 2007, there were 95,183 cancer cases (47,250 males, 47,933 
females) diagnosed among nationals of the GCC states. Breast cancer was the 
most common cancer in almost all the GCC countries. It represented 11.8% of 
all diagnosed cancers in both genders and 23.5% of the total female cancer 
cases.  
 
Figure 2-1: Age standardized incidence rate of female breast cancer in the GCC States, 1998- 2007. 
Note:	  Figure	  created	  using	  data	  from	  (Al-­‐Madouj	  et	  al.,	  2011)	   
 
 Figure 2-1 illustrates the age standardized incidence rate (ASR) of female 
breast cancer in GCC countries between 1998 and 2007. The overall ASR for all 
GCC states was 18.8 per 100,000 women. The highest incidence was reported in 
Bahrain with ASR of 54.4 per 100,000 women, followed by ASR of 48.0 and 






















the ASR was 25.2/100,000 women. The lowest incidence of breast cancer was 
reported in Oman (15.7) and KSA (15.6).   
Differences in reproductive factors could partially explain the gap in observed 
rates between high incidence countries (Bahrain, Kuwait and Qatar) and low 
incidence countries (UAE, Oman, and KSA). Fertility rates were higher in the 
low incidence countries and breastfeeding duration was reported to be shorter 
among females residing in Qatar and Kuwait compared to other GCC countries. 
There has been a reduction in breastfeeding time in all the GCC countries along 
with a steady rise in the age at first childbirth (Ravichandran and Al-Zahrani, 
2009). Along with the decrease in fertility rate, there was a rapid increase in 
usage of contraceptives among GCC women. Moreover, UAE is the only GCC 
country that has established a screening program and this factor might account 
for the higher incidence rate to some extent (Al Khaja and Creedon, 2010).  
There is no current comprehensive review of the completeness and quality of 
cancer registration in all of the GCC countries which might explain some of the 
differences seen in breast cancer incidence among Gulf countries. However, 
there is a suggestion that cancer incidence in Saudi Arabia and UAE might be 
under-reported (Al-Mahrouqi et al., 2011).  Al-Mahrouqi et al. (2011) provided 
some evidence for this suggestion after analysing data from three different 
resources, the Cancer Incidence in Five Continents reports (published by the 
International Agency for Research on Cancer, IARC), the IARC Globocan 
database (which contains country-specific estimates of cancer incidence 
throughout the world in 2002) and the GCCR report. The Cancer Incidence in 
Five Continents report publishes cancer incidence data from cancer registries 
from all over the world, but only data of sufficiently high quality and 
completeness are included. Only three of the GCC countries: Bahrain, Kuwait 
and Oman were included in the latest report (Curado et al., 2008). Data 
submitted by Saudi Arabia were excluded because of concerns about 
completeness, while UAE and Qatar did not submit data. The Globocan 
estimates of cancer incidence rates for Oman, Qatar, Bahrain and Kuwait were 
based on the original data from these four GCC countries and thus were similar 
to those published in the GCC cancer incidence report 1998–2002 (Ferley et al., 
2010). However, because under-reporting was suspected on data from Saudi 
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Arabia and UAE, their incidence rates were estimated using data from Oman, 
Kuwait, Israel, and Jordan (Ferley et al., 2010). Therefore, the resulting 
incidence rates were higher than those published in the GCCR report. The 1998 
- 2002 GCCR report also revealed a very high percentage of microscopic 
verification as a basis for diagnosis in Saudi Arabia, a quality indicator which 
suggests that some cases could have been missed. 
 
Figure 2-2: Average annual age specific incidence rates of breast cancer, 1998-2007 
Note:	  Figure	  created	  using	  data	  from	  (Al-­‐Madouj	  et	  al.,	  2011)	   
With regards to the histopathology types, infiltrating duct carcinoma was the 
most commonly occurring type. 57.8% of all diagnosed types of breast cancer 
showed metastasis and only 22.2% of tumours were localised.  
For all GCC countries, breast cancer incidence gradually increased with age 
(Figure 2-2). In Bahrain, Kuwait and Qatar, the highest incidence was reported 
among women aged 65-70 years. In Qatar, the incidence peaked at age between 
45-50 years. In Oman the highest incidence was observed among women aged 
50-60 years and the highest incidence was observed in Saudi women aged >40 
years. As with most developing countries and due to change in lifestyle, breast 
cancer seems to be increasing over time in all GCC countries. Between 1998 
and 2007, there was a 20% increase in number of new breast cancer cases 




























2.1.1 Cancer registration in Oman 
The Oman National Cancer Registry (NCR) was established in 1985 as a 
hospital- based registry. Only cases treated in tertiary hospitals were registered. 
In 1996, the cancer registry started functioning as a population based registry. 
By 2000, a cancer notification form was created and distributed to all hospitals 
to record patient’s details.  In 2001, cancer notification by hospitals was made 
mandatory. In December 2004, radiotherapy services became available in Oman 
in addition to the other modalities of treatment, which already existed. This 
minimised the number of patients sent abroad for treatment and provided the 
registry with an extra source of cancer notification. Details of the patients sent 
abroad for treatment (mainly for radiotherapy) were obtained from the 
Department of Treatment Abroad and from Tuwam Hospital (the main referral 
hospital for radiotherapy in the neighbouring United Arab Emirates) (Curado et 
al., 2008). Cancer data from Oman were included in the publication of the 
IARC, Cancer Incidence in Five Continents, both 8th and 9th editions (Parkin et 
al., 2002) (Curado et al., 2008). 
2.1.2 Epidemiology of breast cancer in Oman  
 
Figure 2-3: Age standardized incidence rate * of breast cancer in Omani women, 1999-2011 
* Age standardized using the World Standard Population of Segi.	  
Note:	   Figure	   created	   using	   data	   reported	   in	   the	   Omani	   cancer	   incidence	   reports	   (Al	   Lawati	   et	   al.,	  
2013)	  
Breast cancer is the most common cancer among females in Oman. Figure 2-3 
demonstrates the ASR of breast cancer per 100,000 women in Oman from 1999 
to 2011. The incidence of breast cancer has been rising over the years. It was 
13.8 per 100,000 women in 1999 and rose to reach 25.5 per 100,000 women in 





















Oman: 6 males and 156 females of which 9 cases were carcinomas in situ. This 
accounted for 24.8% of all cancer in Omani women. 
 
 Figure 2-4: Age standardized incidence rate of breast cancer in Oman and some selected countries 
Note:	  Figure	  from	  (Al	  Lawati	  et	  al.,	  2013) 
The incidence of breast cancer in Oman is in line with that in other developing 
countries but it is much lower than those reported in industrialised countries 
such as the United Kingdom (UK) and US (Figure 2-4). It has been suggested 
that the relatively lower incidence in Oman (15.7/100,000) is due to the still 
prevalent traditional cultural practices like the early age of the mother at 
childbirth, and multi-parity practiced in most regions in the country (Nooyi and 
Al-Lawati, 2011).  
Breast cancer rates in Oman increase after 29 years of age and peaked between 
50-59 years, unlike cancers in other sites like stomach and cervix, which 
increase gradually with age (Figure 2-5). 	  
 
Figure 2-5 Age-specific incidence rates of common cancers in Omani females, 1998-2006 
Note:	  Figure	  from	  (Nooyi and Al-Lawati, 2011) 
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Incidence according to regions of Oman in 2011 is shown in Figure 2-6. High 
incidence is reported in Muscat (28.2 per 100,000 women) followed by 19.3 in 
Dhofar, 17.4 in Musandam, 12.2 in Adakhliyah and 11.4 in Adhahirah. 
Incidence rates below 10 per 100,000 women were reported in rest of the 
country. The high frequency of cancer reported from Muscat could be biased 
since the majority of the cancer cases are referred to the Royal Hospital in 
Muscat, and people sometimes give a local address in Muscat, rather than 
giving their original place of residence. 
 
Figure 2-6: Incidence of breast cancer by region (incidence rate are per 100,000 populations) 
Note:	  Figure	  from	  (Al Lawati et al., 2013) 
2.2 Breast cancer in the Arab population 
By 2004, the Arab world had a population exceeding 300 million, living in 22 
countries spread across Northern Africa and Western Asia (El Saghir et al., 
2007). There are many shared demographic features among Arab countries 
 25 
including large family size, high rates of consanguinity, and rapid population 
growth (Najjar and Easson, 2010).  
As with most countries in the world, breast cancer is the most frequent cancer 
among females in Arab population (Salim et al., 2009). It accounts for 14-42% 
of all tumours diagnosed (Chouchane et al., 2013). Though the incidence of 
breast cancer in Arab countries is low compared to countries in Europe and 
America, it is steadily increasing (El Saghir et al., 2007).  
Despite the fact that breast cancer is poorly researched in Arab nations, it was 
noted across published studies that breast cancer in Arabs manifests different 
characteristics when compared to nations in Europe and America. In particular, 
Arabs are diagnosed on average at a younger age.  They have more advanced 
stages of cancer at diagnosis with larger and more poorly differentiated 
tumours. Additionally, they show more lymph node involvement and a large 
proportion of negative hormonal receptors (Shaheen et al., 2011, Chouchane et 
al., 2013, Zidan et al., 2012, Salim et al., 2009). 
 Breast cancer in younger women has been shown to have poorer 
clinicopathological features, which indicate aggressive behaviour (Chouchane et 
al., 2013). Tumours tend to be larger in size, lymph nodes positive, poorly 
differentiated and show higher oestrogen and progesterone receptors negativity 
and higher Human Epidermal Growth Factor Receptor-2 (HER-2). Indeed, 
supporting results have been documented in different Arabic studies, for 
example, a study carried out in Tunisia reported that 81% of patients with breast 
cancer had a tumour size of >2 cm in diameter, 34% had a tumour size of >5 cm 
(Missaoui et al., 2011). Further, 48% of cancers were at stage II, 41% were at a 
more advanced stage (stage III and IV), and only 11% had early stages (0 and I). 
In another study comparing Arabs and Jews with breast cancer, Zidan et al. 
(2012) reported that smaller tumour size < 2cm was more common among Jews 
compared to Arabs (53% and 25%, respectively). Additionally, nodal 
involvement was present in 64% of Arab compared to 37.2% of Jews, and stage 
I disease was present in 42% and 11.3% respectively. Similarly, when 
comparing French with Arab Mediterranean populations, tumours were smaller 
in French patients, and grade III predominated in Arab patients (Chalabi et al., 
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2008). Similar patterns of tumour size, grade and staging have been reported in 
studies from Arab countries (Alshatwi et al., 2012, Al-Ajmi et al., 2012, Al-
Tamimi et al., 2009). 
It has been reported in many studies from the US and Europe that younger age 
at diagnosis is a predictor of low survival rates (Najjar and Easson, 2010, Albain 
et al., 1994, Fowble et al., 1994, El Saghir et al., 2006).  In Lebanon, a review of 
1320 patients with breast cancer concluded that younger age at presentation is 
also an independent adverse prognostic factor (El Saghir et al., 2006). 
Interestingly, this negative impact is retained in younger patients studied despite 
the fact that they had an increased rate of positive hormonal receptors and 
received more aggressive chemotherapy than older patients. In contrast, reports 
from other developing countries like Saudi Arabia and Singapore found that 
younger age had no impact on survival of breast cancer patients (Chia et al., 
2004, al-Idrissi et al., 1992). 
Women in the Arab world are diagnosed on average a decade earlier then 
western individuals. In a review carried out in 18 articles from the Arabic 
countries, it was calculated that the average age at diagnosis was 48 years 
(Najjar and Easson, 2010). 11 out of the 18 articles reviewed reported that 
65.5% of breast cancer patients were younger than 50 years old. In Saudi 
Arabia, 78% of the diagnosed patients were below 50 years (Ezzat et al., 1999). 
Published statistics from western countries show that the median age at 
diagnosis is around 63 years and only 25-30% of breast cancer patients are 
younger than 50 years (Chouchane et al., 2013). Similar results come from a 
study comparing North Mediterranean (France) with South Mediterranean 
(Tunisia, Morocco, and Lebanon) (Chalabi et al., 2008). Northern patients were 
on average 60.1 years old when diagnosed whereas southern patients were 49.1 
years old. Tunisian patients were on average more than 13 years younger.  
Interpretation of differences in age at diagnosis of breast cancer observed in 
Arab population and other low risk countries is controversial (Hemminki et al., 
2011). While some have attributed the difference to a cohort effect of rapidly 
increasing rates in the young population, others attribute it to incomplete 
registration of cancer in older patients. Others have suggested that it is caused 
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by differences in tumour biology, which are assumed to vary between low-risk 
and high-risk ethnic groups or regions because of genetic and environmental 
risks factors (Hemminki et al., 2011). 
Evidence seems to show that Middle Eastern Arab women have a tendency to 
manifest a high-grade pathway in breast cancer development. Striking evidence 
appears in an analysis of two consecutive breast cancer series from Switzerland 
and Saudi Arabia (Al-Kuraya et al., 2005). 65% of Saudi patients had grade III 
tumours and only 32% were diagnosed with grade III in Switzerland. 
Consequently, Saudi women appear to have an almost 14-fold lower risk for 
developing lower grade breast cancer than Swiss women. However, further 
study is required to assess this finding in other Arab populations. 
2.2.1 Risk factors of breast cancer in the Arab population  
Hereditary	  risk	  factors	  	  
Recently there have been some studies describing different variations in genetic 
presentation of breast cancer in Arab population and their contribution to breast 
cancer risk. Because the genetic aspect of breast cancer is beyond the scope of 
this research, only a brief account of common genetic variations will be 
described here.  
It is estimated that 5-10% of breast cancer cases are hereditary (Mahfoudh et al., 
2012, Shan et al., 2012, Bener et al., 2010), in which 4-5% are caused by high 
penetrance genes inherited in an autosomal dominant pattern (Chouchane et al., 
2013). Breast cancer gene1 (BRCA1) and BRCA2 genes are two such genes 
that play a substantial role in developing breast cancer (El-Harith et al., 2002). 
BRCA1 carriers have 47-66% risk of developing breast cancer and the risk is 
40%-57% in BRCA2 carriers (Litton et al., 2012). BRCA genes mutations 
explain some of breast cancer risk in Arab world. In recent years, few published 
studies have emerged to describe frequency and spectrum of BRCA mutations 
in Arab countries. It was suggested that BRCA aberrations could be higher in 
Arab women compared to other populations (Rouba et al., 2000). In Tunisia, a 
study screened 16 high-risk breast cancer families for BRCA1 mutations and 
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calculated the frequency to be 37.5%(Mahfoudh et al., 2012). The study also 
revealed a founder mutation in Tunisian patients.  
A Lebanese study found nine carriers of BRCA deleterious mutations among a 
cohort of 72 related patients with breast cancer (Jalkh et al., 2012). 21.8% of 
identified variants on BRCA genes were novel to this study population. Atoum 
and Al-Kayed (2004) studied a total of 135 Jordanian women with breast cancer 
for BRCA1 mutations. Only 50 patients had a family history of breast cancer 
and five germline mutations were identified in these patients given that only 
parts of the gene were screened. Another result comes from a pilot study of 43 
Omani women with breast cancer, which reported duplication and deletion in 
BRCA1 at a rate of 9.7% (Al-Ansari et al., 2013). These results are similar to 
other published studies in the US (8%) and France (9.6%) (Al-Ansari et al., 
2013). 
Most studies in different populations reveal that patients with BRCA mutations 
have a risk of an early onset breast cancer and they are usually younger 
compared to non-mutation carriers at the age of cancer diagnosis (Tommasi et 
al., 2005, Mahfoudh et al., 2012). Litton et al. (2012) assessed the age at 
diagnosis of breast cancer in two generations of families with known BRCA 
mutations. The study reported a median age at diagnosis of 48 years in the older 
generation and 42 years old in the younger generation concluding that BRCA 
mutations carriers appeared to be diagnosed at an earlier age in later 
generations. Accordingly, BRCA mutations might provide some explanation for 
the younger age at diagnosis observed in Arab population. Nevertheless, much 
larger cohort studies are needed to assess the spectrum of BRCA mutations in 
Arab women. Further evaluation of theses studies is vital to suggest the 
appropriate interventions and timing for initiating screening programmes (Hall 
et al., 2009, Litton et al., 2012, Chouchane et al., 2013, Mahfoudh et al., 2012). 
The National Comprehensive Cancer Network guideline stated that carriers of 
BRCA mutation should be educated and trained in Breast Self-Examination 
(BSE) by the age of 18 and should undergo semi-annual Clinical Breast 
Examination (CBE) by the age of 25 years (Daly et al., 2010). Also it 
recommended that women should begin having annual mammography or MRI 
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performed by the age of 25 years or otherwise an individualized timetable based 
on the earliest age of cancer onset in family members should be developed.  
Single Nucleotide Polymorphism (SNPs) contributes to genetic predisposition 
of breast cancer (Shan et al., 2012, Alawadi et al., 2011). Though SNPs are of 
low penetrance susceptibility, together with nutritional and environmental 
factors, they can affect breast cancer risk (Chouchane et al., 2013). Common 
SNPs occurs in TP53 gene. TP53 is a tumour suppressor gene that is regulated 
by MDM2 gene and polymorphism in both genes may be associated with 
increased risk for breast cancer. A case-control study of 100 Saudi breast cancer 
patients reported a statistically significant association between TP53-72 Pro/Pro 
and MDM2 309 GG genotypes with increased risk (Alshatwi et al., 2012). 
Moreover, carriers of both genotypes had a much higher risk for breast 
neoplasms. However, different results were concluded in another genotyping 
study of 288 patients and 188 controls from Kuwait and Syria (Alawadi et al., 
2011). Data showed that frequency of TP53-72 Pro/Pro allele was higher in 
controls than in cases, meaning that it is a protective factor.  
These findings suggest that the Arab population presents with different genetic 
susceptibility patterns compared to other populations and that differences in 
biological and clinical characteristics of tumours may be due to the high 
frequency of pertinent genetic risk factors that are unique to Arab.  
Consanguinity	  
Acquiring two copies of the gene (homozygosity) is associated with increased 
risk for many cancers. Homozygosity increases among children of 
consanguineous parents and therefore they have higher risk of cancers (Denic et 
al., 2007). In Arab countries, the prevalence of consanguinity is about 40-68%, 
with marriage predominantly between first cousins (Bener and Alali, 2004). 
Studies undertaken to examine the effect of consanguinity on breast cancer have 
yield contrasting results.  For example, the population of Pakistan has been 
reported to have the highest rate of breast cancer of any Asian population and 
the overall frequency of consanguineous marriage is 60-76% among Pakistani 
(Gilani and Kamal, 2004). On the other hand, other results show a high rate of 
consanguinity was associated with a decreased risk of breast cancer(Denic et al., 
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2005, Denic and Bener, 2001). Similarly, parental consanguinity was higher in 
controls than in cancer patients residing in Qatar (Bener et al., 2010). It is 
suggested that offspring of consanguineous parents will have acquired two 
copies of deleterious genes that are important in both development of breast 
cancer and at the same time development of normal embryo (Denic and Bener, 
2001). Accordingly, these genes impair embryogenesis, perinatal or postnatal 
development resulting in abortions or stillbirths, which are noticed to be high 
among consanguineous parents. Some of these lost embryos are actually ‘lost 
breast cancer patients’ and therefore the long-term practice of consanguinity 
may decrease the frequency of such deleterious genes.   
Infections	  
Viruses have been reported to be associated with development of several 
cancers (Serraino et al., 2001). Epstein-Barr Virus (EBV) has been detected in 
neoplastic tissues of breast cancer patients. A case-control study was conducted 
with 40 Egyptian and 50 Iraqi patients to assess the association between EBV 
and breast cancer (Zekri et al., 2012). Interestingly, EBV was detected in 45% 
of Egyptian and 28% of Iraqi patients, while it was absent in the control groups 
of both populations. These findings suggest that EBV might have a role in the 
development of breast cancer. 
Obesity	  	  
Obesity is an established important prognostic risk factor for breast cancer 
particularly in postmenopausal women (Sharma and Davidson, 2013, 
Henderson et al., 2010). Usually, obese patients exhibit more aggressive 
tumours with higher tendency to metastasis (Alokail et al., 2013). Metabolic 
Syndrome (MS) is defined by the presence of obesity together with Diabetes 
Mellitus Type 2. MS prevalence is reported to be increasing in the Arab world. 
Prevalence of MS in men residing in GCC areas ranged from 20.7%-37.2% 
while it ranged from 32%-42.7% for women (Mabry et al., 2010). It is 10-15% 
higher than in most developed countries with the difference being higher for 
women. Alokail et al. (2013), (2009) demonstrated in two published studies 
from Saudi Arabia that patients with MS have a higher risk of developing breast 
cancer. Altered expression of inflammatory markers (such as Angiotensin II, C 
reactive protein and Leptin) observed in those patients may enhance 
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tumorigenic activity leading to breast cancer aetiology (Alokail et al., 2009). 
The magnitude of the effect of MS on breast cancer risk in other Arab countries 
should be considered because intervention programmes for MS may contribute 
to reduction in breast cancer incidence. 
Reproductive	  factors	  	  
With regards to reproductive factors and their contribution to breast cancer risk, 
a study carried out in the GCC concluded that difference in incidence rate in 
GCC countries reflects the history of reproductive factors of each country 
(Ravichandran and Al-Zahrani, 2009). Reproductive patterns in the GCC 
countries are characterised by an early start of childbearing, short birth intervals 
and ultimately high parity. Fertility rates in high incidence countries were low 
compared to those in low incidence countries. Moreover, there was a steady rise 
in the age at first birth over time and this decline in early childbearing age was 
more rapid in high incidence areas than in low incidence. 
2.3 Women’s perception of breast cancer risk 
Perceived risk refers to an individual’s belief about the probability or likelihood 
of developing some specified illness (McQueen et al., 2008). For example, a 
sample of 41 women recruited from Atlanta described breast cancer as a 
uniformly progressive disease, which is curable if found at an early stage, but 
deadly if found late (Silverman et al., 2001). Although “benign” disease of the 
breast is biologically classified as a separate entity from breast cancer, there 
were those who believed that “benign condition” of the breast is a stage in 
progression to malignancy (Silverman et al., 2001). More specifically, breast 
cancer is perceived to convey a substantial and real threat to women’s health, 
their bodies, and their sense of future self (d'Agincourt-Canning, 2006). 
McGregor et al. (2004) found that when a sample of women from US were 
asked, ‘compared to most women, what do you think the chances are that you 
will get breast cancer someday?’ their mean response was a little higher than 
the average women. When asked, ‘ What do you think the chances are that the 
average woman will have breast cancer some day?’ their mean response was 
30%-40%. However their response lowered to 20%-30% when they were asked, 
‘What do you think the chances are that you will have breast cancer someday?’  
 32 
When using the Gail model to estimate the actual risk, it has been found that the 
mean estimated absolute risk for this sample was 10.5%, which implies that this 
sample of women has overestimated the risk. In another study Grunfeld et al. 
(2002) looked closely at the age and perceived risk. His study demonstrated a 
relationship between age and the perception of risk with 35% of over 65-year-
olds and 30% of over 75-years-olds reporting reduced personal risk.  
 It appears there are two distinct groups of women in relation to the their 
perceived breast cancer risk; those who believe that they are at a high risk of 
getting breast cancer and overly stressed about it and those who think that they 
will never get it and so they ignore it (d'Agincourt-Canning, 2006, Bryan, 
2002). These perceived estimates of risk have a relationship with experience. 
Researchers have found that women who have a family history of the disease 
usually overestimate their risk and this is demonstrated in many genetic 
counselling clinics and family history clinics (Absetz et al., 2000, Vernon et al., 
1993, McQueen et al., 2008, Anderson et al., 2002, Katapodi et al., 2004, 
MacDonald, 2002). Familial breast cancer accounts for approximately 15% to 
20% of overall breast cancer cases (Saadatmand et al., 2013). Indeed there is a 
high risk of developing breast cancer among those who have an affected first 
degree relative compared to the general population, especially if diagnosed at 
younger age. The risk of breast cancer for women with one, two, and three or 
more affected first-degree relatives, when compared with women not having a 
first-degree relative with a history of breast cancer, were 1.8, 2.9, and 3.9 
respectively in a large UK cohort (Beral et al., 2001).  Therefore, it is not 
surprising   that woman with a family history have perceived a high risk.   
Risk perception is created within the mind of the individual based on many 
factors (Slovic, 1999). Rothman et al. (1996) indicated that both psychological 
and contextual factors could affect perception of risk. Psychological factors 
related to breast cancer risk perception might include breast cancer worry and 
anxiety. Contextual factors related to breast cancer might include such things as 
family history/genetics, one’s own health behaviours, the history of benign 
breast disease, and beliefs about risk factors.  Findings have indicated that the 
majority of women have poor understanding and lack knowledge about the 
disease risk factors (Grunfeld et al., 2002, Williams et al., 2002). A significant 
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number of studies demonstrate that many of the risk factors identified were 
modifiable factors that are weakly, if at all, associated with breast cancer 
(Buxton et al., 2003, Silverman et al., 2001). Most recognized the importance of 
“uncontrollable” factors for breast cancer such as age, sex, family history, and 
genetics. Family history was the most recognizable risk factor across the 
literature (Buxton et al., 2003, Grunfeld et al., 2002, Williams et al., 2002). 
However, other “controllable” factors (e.g., smoking, diet) were given equal or 
greater importance, which suggests that many women feel responsible for their 
level of breast cancer risk (Silverman et al., 2001). 
Although advanced age is the most important risk factor for developing breast 
cancer, several studies revealed that it was poorly understood by the vast 
majority of women (Vernon et al., 1993, McQueen et al., 2008, Katapodi et al., 
2004). This belief often acquired by women over the age of 60 years who 
provided an explanation that they are too old to develop breast cancer, ‘I think if 
I was going to develop it, I would have by now’ (Grunfeld et al., 2002). In the 
UK, women aged 50-64 are usually offered breast cancer screening and this 
might contribute to high-risk perception among this group. However, it sends 
the wrong message to women over the age of 64 years who think they are no 
longer at risk, ‘At my age I think the danger has passed’, ‘[Because] they stop 
mammograms at 65’ and ‘I think older people are less likely to have breast 
cancer problems’ (Grunfeld et al., 2002).   
Understanding the actual risk of developing breast cancer is important for 
women because it influences their decisions to adopt preventive actions such as 
engaging in healthy lifestyle behaviours including regular physical activity, 
increasing fruit and vegetable intake and consumption of a low-fat diet for 
weight control, and limiting alcohol intake and health care such as genetic 
counselling and hormonal replacement therapy (Katapodi et al., 2004, Bottorff 
et al., 2004, Haas et al., 2005, Lemon et al., 2004). Also risk perception has a 
role in enhancing appropriate participation in recommended screening (Absetz 
et al., 2000, Buxton et al., 2003, Hailey et al., 2000). In addition, such 
knowledge is important in improving one’s quality of life because 
misperception of personal risk, especially among those who overestimate their 
risk, has been linked with excessive worry, anxiety, neglecting the importance 
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of other high-risk diseases, and causing psychological distress (Buxton et al., 
2003, McGregor et al., 2004, Bottorff et al., 2004, Hailey et al., 2000, Williams 
et al., 2002). In contrast, women who underestimate their risk are susceptible to 
the threat of ill health as a result of deferring screening and not involving 
themselves in risk reducing behaviours (Haas et al., 2005, Williams et al., 
2002). A study in the UK found that women who perceived a high risk of 
developing breast cancer (such women with family history) experienced 
heightened levels of worry and stress leading to increased performance of BSE 
and other reducing techniques (Norman and Brain, 2005). On the other hand, 
women with no experience or limited knowledge of breast cancer and who 
perceived themselves of having low risk of developing the disease are highly 
unlikely to undertake any early detection or knowledge/awareness raising 
techniques (Williams et al., 2002, Haas et al., 2005, Norman and Brain, 2005). 
Nevertheless, it was demonstrated that women with the highest objective risk 
for breast cancer do not report healthier lifestyle behaviours suggesting other 
important factors that might play a role in motivating behavioural changes 
(Madlensky et al., 2005, Spector et al., 2009). Such factors include inadequate 
knowledge about known risk factors, lack of personal control, lack of 
motivation and additional roadblocks towards healthy behaviours (Spector et al., 
2009).  
In summary, woman’s perception of her risk for developing breast cancer 
influences her decision to undertake health actions such as seeking evaluation of 
new breast symptoms and also to involve in preventive actions such as 
screening programs.    
2.4 Delay in seeking medical care in patient with breast cancer 
The period of time between a woman’s first noticing a breast cancer symptom 
and receiving treatment for this can be referred to as 'delay' or ‘total delay’ 
(Unger-Saldaña and Infante-Castañeda, 2009). Delay in seeking medical help 
contributes to advanced-stage presentation (Unger-Saldaña and Infante-
Castañeda, 2009). Patient delay has been associated with increased tumour size, 
increased involvement of the lymph nodes, more advanced stages of the disease 
and poor long-term survival (Unger-Saldaña and Infante-Castañeda, 2009). A 
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systemic review of 87 studies with direct data linking delay and survival 
concluded that patients with a delay of three months or more had 12% lower 
five-year survival than those with a shorter delay (Richards et al., 1999b). A 
patient with a significant delay may have worse prognosis simply because she is 
further from the onset of disease and not necessarily because treatment has not 
been initiated.  Patients with a delay of 3-6 months had 7% lower survival rate 
than those who sought medical help earlier (Richards et al., 1999b).  This 
finding of delay associated with worse survival rate is strongly supported by 
another meta-analysis of 21 studies on patient delay (Bish et al., 2005). In 
addition, the review found an association between longer duration of symptoms 
and advanced tumour stage, which has been documented in several countries 
like Iran (Montazeri et al., 2003), Egypt (Stapleton et al., 2011), Germany 
(Arndt et al., 2002), Malaysia (Norsa'adah et al., 2011) and Thailand.  In 
Thailand, for example, a study reported that patients with TNM stage III disease 
had a median delay of presentation of two months compared to seven months 
for those in stage IV (Thongsuksai et al., 2000). Similarly, a cross sectional 
study carried in Egypt found that while 26.3% (88/335) of women with < 3 
months delay were at stage III and IV, the corresponding proportion among 
women with >3 months delay was 72.1% (Abdel-Fattah et al., 1999).  
Traditionally, breast cancer delay has been classified into two types: patient 
delay and provider delay. The term ‘patient delay’ was first introduced by Pack 
and Gallo in 1938 and it is defined as "the period between an individual's first 
awareness of a sign or a symptom of illness and initial medical consultation" 
(Pack and Gallo, 1938). Terms like 'help seeking delay', 'help-seeking 
behaviour', 'late presentation' and 'consultation delay' are frequently used 
synonyms for  ' patient delay' in the literature.  
‘Provider delay’ refers to the period of time between the initial medical 
consultation and definitive treatment of cancer (Unger-Saldaña and Infante-
Castañeda, 2011). This includes the time between visiting the general 
practitioner and referral to the hospital, between first hospital visit and cancer 
diagnosis and the period between diagnosis and treatment (Bish et al., 2005).  
Based on the meta-analysis carried by Richards et al in (1999b) which found a 
significant association between delay of longer than three months and worse 
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rates of survival, the most accepted threshold for patient delay is three months 
and one month for ‘provider delay’.  
Several studies have been conducted to explore breast cancer delay in developed 
and developing countries. For instance, a study conducted in Iran reported that 
68% (136/200) of cases had delayed their first visit by ≥1 month and 42.5% by 
≥3 months with median patient delay of 12 weeks (Harirchi et al., 2005). 
Likewise patient-related delay of more than three months was found in 38.1% of 
Egyptian patients (Abdel-Fattah et al., 1999). The median interval between the 
discovery of the first symptom and the first visit among all patients was five 
weeks (ranging from 1 to 192 weeks).  Thongsuksai et al. (2000) from Thailand 
reported a median delay of eight weeks in patients with stage III disease and 28 
weeks in patients with stage IV disease. Similar figures come from a study 
conducted at five large medical centres in Malaysia where the frequency of 
diagnosis delay of more than three months was 72.6% and delay of more than 
six months occurred in 45.5% of the cases (Norsa'adah et al., 2011).  
Patient delay of three months was reported to range from 14% to 19% in 
developed countries (Pineros et al., 2009). In a large study from the UK, 
Richards et al (1999a) reported a prevalence of patient delay (>12 weeks) of 
55.5% in women with locally advanced breast cancer. This percentage rose to 
67.3% in metastatic cases. In Germany, the median patient delay was 16 days 
but one out of six women (17.4%) waited more than three months before 
seeking professional health care (Arndt et al., 2002). In New Zealand, out of a 
total sample of 85 women, 40% had seen their doctor within seven days, 52% 
within 14 days, 69% within 30 days, and 14% had waited over 90 days 
(Meechan et al., 2002). 
Many studies have been conducted to identify the factors that contribute to 
delay in seeking treatment and a variety of socio-demographic, clinical and 
psychosocial factors have been examined in relation to patient delay in seeking 
treatment (Rastad et al., 2012). These studies have, however, presented varying 
and contradictory results. A systematic review was undertaken to identify the 
explanatory factors and assess the strength of the evidence for the determination 
of late or delayed presentation for breast cancer in the Middle East. It included 
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six studies from Iran and Egypt and found strong evidence in the association 
between older age and patient delay (Alhurishi et al., 2011). This was because 
there were three studies (Abdel-Fattah et al., 1999, Elzawawy, 1999, El-
Zawawy, 1991) which demonstrated a positive association between older age 
and patient delay with a large study population (a total of 827 patients) 
compared to two studies (Stapleton et al., 2011, Montazeri et al., 2003) showing 
negative association with 533 patients. The review also found that lower 
education levels were strongly associated with longer delay where in Egypt 
delayed presentation was 13 times greater for illiterate women compared with 
university graduates (Abdel-Fattah et al., 1999). Ramirez et al. (1999) 
concluded that there was strong evidence that patient delay was associated with 
older age but moderate evidence that patient delay was associated with fewer 
years of education in a systematic review of 23 studies on patient delay and 
breast cancer. Several reasons might explain patient delay in older women. 
Older women may attribute their symptoms to existing chronic conditions or to 
aging (Arndt et al., 2002). Grunfeld et al. (2002) stated that older women were 
less likely to perceive changes in breast skin and change in breast shape or size 
as symptoms of breast cancer. In addition, it has been argued that older adults, 
who suffer from other illnesses, are less likely to seek medical help for 
symptoms that are not causing them pain or that have a minor impact on their 
daily function (Grunfeld et al., 2002). Failure to identify breast cancer 
symptoms and poor knowledge about breast cancer risk factors have been 
demonstrated among older women (Grunfeld et al., 2002) (Bish et al., 2005). 
Similar findings to Ramirez et al. (1999) were found in a systematic review of 
patient delay in developing countries, which included 13 studies from Thailand, 
Egypt, Pakistan, Iran, Nigeria, Tunisia, Malaysia, Colombia, India and Ghana 
(Sharma et al., 2012). While some studies found no association between patient 
delay and marital status (Abdel-Fattah et al., 1999, Elzawawy, 1999, Ramirez et 
al., 1999, Bish et al., 2005) other studies found that being married (Harirchi et 
al., 2005), or being divorced or widowed (Montazeri et al., 2003, Ali et al., 
2008) resulted in longer delays. With respect to income status, Sharma et al. 
(2012) concluded in their systemic review in developing countries that “the 
predominant theme emerging from the results of this review emphasizes how 
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poverty constitutes the underlying common denominator and (was the) most 
important barrier contributing to delayed patient presentation in these settings.”  
The causal conditions of poverty are supported by evidence from both “good” 
and “fair” studies and are chiefly manifested economically via lower income 
status, lower education levels, rural residency, and lack of access to healthcare 
systems". It is easy to see how lack of financial resources to use health services 
is significantly associated with longer delay, as one Mexican patient described 
it: “Money is everything, isn't it? For transportation, for medication, for 
everything that you need to pay at the hospital” (Unger-Saldaña and Infante-
Castañeda, 2011).  
Lack of knowledge regarding breast cancer has been linked with patient delay in 
several studies (Stapleton et al., 2011, Abdel-Fattah et al., 1999, Harirchi et al., 
2005, Rastad et al., 2012). Failure to identify and label the initial symptoms 
influences a woman’s decision to seek medical help immediately (Norsa'adah et 
al., 2011, Burgess et al., 2001). Interpretation of breast symptoms is based on 
the pre-existing knowledge, experience, self-education and observation of 
individuals (Norsa'adah et al., 2011). If the woman has knowledge regarding the 
variation of symptoms in breast cancer, she will be able to interpret and assess 
her symptoms more correctly and decide to seek medical attention. Patients are 
more likely to attribute new symptoms to less serious conditions instead of to a 
life-threatening disease (Bish et al., 2005). A study reported that considering 
symptoms to be harmless was the most important reason for delaying 
consultation for more than half of the patients (Nosarti et al., 2000). Similar 
results come from the UK where ‘I didn’t realise it was serious’, was a 
frequently comment among patients who delayed (Burgess et al., 2001). 
Perception of the seriousness of a symptom is dependent upon the first symptom 
and how fast the symptom changes and multiplies. Burgess et al. (2001) stated 
that women monitored the situation, keeping their symptoms under review: ‘I 
mentally kept an eye on it and I thought that has got bigger. So I made an 
appointment to go to the doctor’s’ 
False interpretation of the initial symptom was a prevalent and a common issue 
expressed as a main reason for delay in seeking treatment (Rastad et al., 2012). 
Mexican women talked about not knowing the initial symptom they discovered 
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might be a sign of breast cancer (Unger-Saldaña and Infante-Castañeda, 2011). 
Some women confessed that they did not know that inward retraction of the 
nipple, an axillary mass, a painless mass, etc. could be an early sign of breast 
cancer: ‘My breast had no problem at all! Just a little hard lump under my 
arm...’ ‘I went to take a bath… the brown areola was pulled in and a large 
piece … of this side of my breast was very hard... Because it didn’t have any 
pain, I did not think that it was serious’. (Rastad et al., 2012) 
In fact, the nature of presenting symptoms influenced whether or not to delay 
seeking medical help. This fact is demonstrated in the finding that women with 
non-lump symptoms tended to delay consultations compared to those with a 
lump (Burgess et al., 2001, Burgess et al., 1998, Abdel-Fattah et al., 1999, 
Montazeri et al., 2003). It is suggested that symptoms which fail to match the 
expectations of breast cancer presenting as a discrete breast lump may 
contribute to the delay in seeking treatment and that the public perception of the 
presenting symptoms of breast cancer may need to be broadened (Burgess et al., 
2001). In other studies, the absence of pain has been associated with longer 
delay and late stage diagnosis (Burgess et al., 2001, Stapleton et al., 2011). Pain 
is a common symptom of any disease that draws attention to the site of the 
disease. In case of breast cancer, pain is most likely to occur in case of large 
tumours or ulceration both of which are indicative of late-stage disease 
(Stapleton et al., 2011). 
Moreover, knowledge of breast self-examination (BSE) increased the likelihood 
of women presenting in early stages in some studies (Abdel-Fattah et al., 1999, 
Stapleton et al., 2011, Rastad et al., 2012). Lack of knowledge about BSE and 
not having a previous clinical breast examination (CBE) or a mammogram were 
also associated with late stage at presentation (Stapleton et al., 2011). A 
qualitative study carried in Iran noted that the majority of the participants said 
they didn’t practice BSE, while the rest of them pointed out that they did not 
always follow the instructions consistently (Rastad et al., 2012). Another study 
also showed that the knowledge and attitude of Iranian women about breast 
cancer screening and the signs of breast cancer are not enough (Khanjani et al., 
2012). Some did not do breast cancer screening examinations such as BSE 
because they did not believe it was necessary, but most of them did not do it 
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because they did not know how to perform the examination. Similar findings 
come from Egypt where patients who did not practice BSE had nearly 18 times 
higher risk of diagnostic delay as compared to those who practiced it, regardless 
of its regularity (Abdel-Fattah et al., 1999). The benefit of BSE is being debated 
across the literature. Several observational studies, including case-control and 
cohort studies, have examined the effects of BSE in various women populations 
(Muscat and Huncharek, 1991, Newcomb et al., 1991, Holmberg et al., 1997). 
These studies have yielded conflicting conclusions, but the majority have shown 
that BSE failed to detect cancer at earlier stages or improve survival. 
Nevertheless, the results of theses studies have been questioned as being 
unreliable because observational studies have several limitations when they are 
used to examine screening techniques (Corbex et al., 2012). Further, BSE has 
been questioned in view of two randomized trials: one from Russia (Semiglazov 
et al., 2003) and the other from Shanghai (Thomas et al., 2002). The result of 
both trials discredited BSE as a screening tool and showed that it greatly 
increases the number of benign lumps detected. This, too, is the official position 
of health authorities like the US Preventive Services Task Force and the 
Canadian Task Force on Preventive Health Care to issue recommendations 
against teaching BSE, stating, “For the teaching of BSE, there is moderate 
certainty that the harms outweigh the benefits” (Corbex et al., 2012). However, 
some have suggested that enhanced breast health awareness may motivate 
women to seek treatment for breast-related symptoms earlier than women who 
did not know about BSE (Stapleton et al., 2011)  
The association between family history and patient delay among breast cancer 
patients showed contradictory results from different studies. While some studies 
conducted in India (Ali et al., 2008) and New Zealand (Meechan et al., 2002) 
reported positive correlation between family history and patient delay, others 
have reported negative correlation (Harirchi et al., 2005, Montazeri et al., 2003) 
or did not find any significant associations in this regard (Burgess et al., 1998, 
Nosarti et al., 2000). Harirchi et al. (2005) explained that woman with a family 
history perceived a high risk; this might have led to more immediate actions 
upon discovery of a mass. Being familiar with breast cancer through the 
experience of a family member is associated with shorter delays: ‘I never had 
 41 
seen anyone with this problem…if it was so, maybe I would come sooner.’ ‘I 
knew nothing [about breast cancer]… since we did not have it in our family.’ 
(Rastad et al., 2012) 
Other reason for patient delay is what could broadly be defined as the social 
relations of care seeking. Studies have shown that social relations are important 
mediators in care seeking decisions. As Facione (1993) suggested that role 
demands such as devoting time and attention to the needs of someone else and 
taking time to make domestic arrangements prior to having a biopsy taken may 
delay care seeking. Family engagement and career commitments were among 
the common reasons for delay mentioned by Iranian patients (Rastad et al., 
2012). Harirchi et al. (2005) explains that traditionally with respect to women's 
role in the Iranian families, women do not usually have much time for 
themselves as they have to deal with household chores, children’s needs and 
outdoor activities such as shopping. Though some women knew that the present 
signs could be serious, they thought that visiting a doctor and the subsequent 
workup would take too much time, and they would have to sacrifice their family 
responsibilities and job commitments (Rastad et al., 2012): ‘I was scared that if 
I visit a doctor, I may need an operation. My children were too young and I was 
working…’ Likewise in the UK, Burgess et al. (2000) reported that patients who 
delayed did not prioritize their health over competing demands. Others have 
shown that social networks are central triggers for care seeking. Studies show 
that breast cancer patients who do not disclose their symptoms to someone else 
within a week have longer patient delay (Burgess et al., 2006, Burgess et al., 
1998). Disclosing symptom discovery to another person could facilitate 
recognition of the potential seriousness of the situation and the decision to seek 
medical advice, as one patient said: ‘I happened to speak to a friend who had 
breast symptoms in the past ... and she said, ‘You must go straight away’. 
(Burgess et al., 2001) 
Fear appears to be an important psychological factor in delay, and its intensity 
may influence magnitude of delay(Dubayova et al., 2010a). Dubayova et al. 
(2010a) explained that feelings, such as worry, fear and anxiety, could be 
elicited by several factors. Such factors include symptoms which induce pain or 
discomfort, presumed diagnosis and anticipated consequences of treatment, as 
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well as by coping failures and reinterpretations of the illness condition. Across 
the literature on breast cancer and patient delay, fear is a major barrier to early 
medical help (Stapleton et al., 2011, Harirchi et al., 2005, Rastad et al., 2012, 
Burgess et al., 1998, Unger-Saldaña and Infante-Castañeda, 2011).  
Different reasons in different cultural contexts explained this fear. For example, 
African and Afro-Caribbean patients with breast cancer feared they might end 
up having a mastectomy and were concerned about their fertility and ability to 
keep their sexual partners (Rastad et al., 2012). Other patients recognised their 
symptoms to be serious and might be cancerous yet they delayed seeing a doctor 
because they feared the consequences of therapeutic intervention (Norsa'adah et 
al., 2011, Burgess et al., 2001, Rastad et al., 2012). It seems as if the patient was 
convinced that cancer could not be cured or that it would necessitate invasive 
treatments.  
Similar studies reported that some of the participants confessed that because of 
their fear about being diagnosed with cancer, they postponed their medical 
consultation (Rastad et al., 2012). It seems as if they felt safer not knowing that 
they had cancer, even if they suspected it. In patients with different types of 
carcinoma, 17% of the delayers reported fear of discovering the cause of their 
symptoms was the reason for their delay (Dubayova et al., 2010b). These fears 
had often been influenced by past experiences of cancer in relatives or friends 
(Burgess et al., 2001, Rastad et al., 2012). Because of this evidence, some have 
suggested that there may be some benefit in reassuring women of the benefits of 
early treatment on prognosis (Rastad et al., 2012). They should be assured that 
surgery is minimal if the cancer is diagnosed early enough, and that there have 
been advances in the management of the side effects of chemotherapy. Such 
education would need to be informed by more data on current beliefs and 
attitudes about breast cancer and its treatments in the general population. Fear of 
hospitals, operations, and medical tests has been linked to patient’s delay 
(Burgess et al., 2001). 
Negative perception of breast cancer treatment and the use of alternative therapy 
are also explanations as to why women with breast cancer delay seeking 
medical help (Norsa'adah et al., 2011). A negative perception of breast cancer 
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treatment prevented patients from receiving early diagnoses has been 
documented in studies from Malaysia (Norsa'adah et al., 2011), Iran and Nigeria 
(Ajekigbe, 1991). Negative perception of the side effects of chemotherapy 
might induce fear in some patients causing them to refuse treatment. Some 
women hold the belief that treatment would affect their ability to perform their 
role and thus they would have to rely on others to care for them (Norsa'adah et 
al., 2011). Fear of divorce or the husband remarrying could lead some women to 
decide not to get their symptoms diagnosed if they suspected breast cancer 
(Norsa'adah et al., 2011). Others believed that breast cancer could not be cured, 
so there was no point in having it diagnosed and treated (Andersen et al., 2009).  
Diagnosis delay was also related to a belief that mastectomy causes 
disfigurement and disability (Grunfeld et al., 2003). Sharma et al (2012) 
concluded in a systematic review of patient delay in developing countries that 
alternative treatment use including use of other practitioners and use of prayer 
was associated with longer delays. Malaysian patients, for example, used 
alternative therapy as a way to avoid surgery or took it when the prognosis was 
fatal and disease caused suffering (Norsa'adah et al., 2011). It is clear from this 
evidence that women who delay seeking help for symptoms of breast cancer 
have a reduced chance of survival. It is, therefore, extremely important in a 
programme of primary research into understanding the factors that lead to 
increased risk of delay, that it is vital to determine effective approaches to 
shortening of delay and thereby improving women’s survival and quality of life.   
In summary, ‘patient delay’ is defined as the time between the initial 
presentation of symptoms and first medical consultation. The most accepted cut 
off for patient delay is three months. Older age and lower educational levels are 
shown to be associated with longer delay. There were inconsistent results on the 
association between marital status and family history with patient delay. Other 
factors that were identified to be associated with patient delay included lower 
income, rural residency, access to health care services and nature of presenting 
symptoms. Studies also have identified other reasons for longer delay including 
lack of knowledge regarding breast cancer symptoms, knowledge and practice 
of BSE, negative perception of breast cancer treatment, competing demands in 
terms of family and work commitments and finally, fear and embarrassment.  
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Exploring the literature on breast cancer and patient delay helps to identify the 
common factors that are likely to be associated with longer delay. These factors 
will be used in the design of the questionnaire used in this study to assess 




3 Chapter Three: Delay in Seeking Medical Care for 
Self-Detected Breast Cancer Symptoms in Omani 
Women 
3.1 Introduction 
The extent of patient delay in Oman with self-detected breast symptoms and the 
factors influencing this delay time have not been investigated. Published studies 
from Oman found that more than half of the patients presented with advanced 
disease (stage III and IV) (Al-Moundhri et al., 2004, Al-Moundhri et al., 2011). 
So the aim of this study is to address this gap by assessing the magnitude of the 
delay among Omani women presenting with breast cancer and to evaluate 
possible factors causing this delay in order to recommend strategies and 
programs to prevent patient delay in breast cancer diagnosis. 
3.2 Aims 
• To identify the magnitude of the delay in breast cancer diagnosis in 
Oman. 
• To assess the relationship between delay and socio-demographic 
characteristics, medical and obstetric history, nature of presenting 
symptoms and women’s knowledge about breast cancer. 
• To identify reasons for delay in seeking medical help for self-detected 
breast cancer symptoms in Omani women.  
3.3 Methodology 
3.3.1 Sample and sample recruitment  
The population of interest for this research study was women diagnosed with 
breast cancer in Oman. Participants were recruited from two tertiary hospitals in 
Oman, Royal Hospital (RH) and Sultan Qaboos University Hospital (SQUH). 
These two hospitals were chosen because there are the only two main hospitals 
in the country that provide cancer treatment especially chemotherapy. RH has 
the National Oncology Centre, which is the only place in the country that 
provides radiotherapy treatment. Nevertheless, some of the eligible participants 
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for the study might be missed due to the following reasons. First, Eligible 
patients were included after the diagnosis of breast cancer was made and did not 
include those patients who had died before the study was conducted. Second, 
other patients may have stopped attending the follow-up clinics and hence were 
not seen in the clinics at the time of the study. Third, some patients from other 
regions in the country required treatment of conservative surgeries only which 
are sometimes carried out in the regional hospitals and therefore are not seen in 
RH or SQUH.  
Sample size was determined by pragmatic considerations. It was anticipated that 
over four months of data collection in the two hospitals, I would be able to 
interview at least 150 women of whom at least 100 would have been diagnosed 
with later stage disease. In a study of 200 women with stage IIB and above 
breast cancer in Iran, Harirchi et al. (2005) found that 68% had waited for more 
than a month after their first symptom to seek medical care. Of those with delay, 
98% were married compared with 87% of those without delay (p=0.002), and 
52% of those with delay were illiterate compared with 31% of those without 
delay (p=0.04). If my findings were found to be similar to those of Harirchi et 
al. (2005), I would have 68% power to detect the higher proportion married and 
63% to detect the higher proportion illiterate in the delayed group, with 5% 
significance. 
At RH patients attended the oncology outpatient clinic within the National 
Cancer Centre every Tuesday and were approached in the waiting room from 
27th April till 15th July 2013. Also additional patients were approached at the 
chemotherapy day-care unit at the centre every Sunday and Wednesday.  At 
SQUH patients attending the oncology outpatient clinic every Monday from 
13th May to 20th July 2013, were approached and all Thursday patients from 
the chemotherapy day-care room within SQUH were asked to participate in the 
study. 
The initial plan was to get the nurses at the clinics’ reception in both hospitals to 
provide the patients with the information sheet and I was to answer any 
questions from the participants and ask for consent. However, because they 
were very busy clinics and nurses were not always present at the reception, a list 
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with names of attending breast cancer patients was given to me and I 
approached them where they were sitting at the waiting room and asked them to 
take part in the study. Other patients were referred to me after their consultation 
with the doctor. At the chemotherapy unit, I approached patients while they 
were waiting for their blood results before starting the chemotherapy. 
3.3.2 Data collection  
Participants were provided with an information sheet in Arabic and were given 
the opportunity to ask questions if there was anything that they did not 
understand or wanted to clarify. For those who were illiterate, I read and 
explained the information sheet for them.  Then a consent form, which was also 
in Arabic, was completed. There was an emphasis placed on ensuring that the 
participants’ involvement in the research was voluntary and that they were free 
to withdraw at any stage. In addition, patients were asked for permission to 
access their medical notes using their hospital number to confirm any medical 
information like date of diagnosis, if necessary. However they had the option to 
consent to the interview only (if they consented at all). The interview was 
carried out in a private room within the two hospitals.  
Face-to-face interviews were conducted using standardized questionnaires. The 
content of the questionnaire used (see appendix 1) was derived from the existing 
literature on delayed presentation. Each interview took around 15-20 minutes. 
The questionnaire was filled in by me during the interviews. 
The questionnaire consisted of 34 questions. Most of the questions were closed 
questions except for few open questions that used to enquire about reasons for 
delay.  It covered four themes, which were:  
• Socio-demographic characteristic which included age, educational level, 
occupation, family guardian, occupation, house-hold income, place of 
living, travel time to the nearest medical centre and marital status. 
• Obstetric and medical histories, which included number of children, age 
at first childbirth, number of children who are breastfed, breastfeeding 
duration, phase of menopause, weight, height, history of chronic disease, 
family history of breast cancer. 
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• Symptoms and healthcare seeking behaviour which included date of 
diagnosis, stage at diagnosis, detected breast cancer symptoms, date 
when first noticed these symptoms, number of weeks between noticing 
the symptoms and visiting a doctor, reasons to visit the doctor at time of 
diagnosis, reasons for delaying seeing a doctor after discovering the 
symptoms and whether the participant talked about her symptoms to any 
one before she visited a doctor. 
• Knowledge and attitude toward breast cancer which included knowledge 
about breast cancer symptoms, incidence of breast cancer in Oman, main 
method of diagnosing breast cancer, early detection methods, familiarity 
and performance of breast self-examination before and after the 
diagnosis, and beliefs about prevention and cure of breast cancer. 
After the interviews, the supervising doctors at each hospital completed the 
missing information from the patients’ medical records using the hospital 
numbers they provided during the interviews. Such information included, 
patient’s BMI, menopausal stage, date of diagnosis and stage of disease. 
3.4 Variable definition for analysis 
A number of variables were derived from the data collected in the questionnaire 
for use in data analysis: 
• Patient delay: Patient delay was defined as “the period between an 
individual's first awareness of a sign or a symptom of illness and initial 
medical consultation” (Pack and Gallo, 1938). In this study and in line 
with other published studies on patient delay (see section 2.4), patient 
delay was categorised into periods of non-delay (<3 months) and delay 
(≥ 3months). To reduce recall error, the participants were reminded of 
events in the calendar such as school holidays, religious/national 
occasions and birth dates, to help them remember important dates 
relative to their medical history. 
• Age groups: Age was collected from patients and then confirmed using 
medical record of each patient. As mentioned earlier (section 2.1), 78% 
of the Arab population diagnosed are below 50 years compared to only 
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25-30% in the western population (Chouchane et al., 2013). Age was 
categorised into four groups: 27-35 years, 36-49 years, 50-64 years and 
>65 years in order to compare percentage of women below 50 years to 
the rest of Arab populations and western population and also to allow 
comparison with frequency of cases published in the Omani National 
Cancer Registry. 
• Occupation: occupations were classified according to the “Australian 
and New Zealand Standard Classification of Occupations” available at 
Statistics New Zealand website: 
http://www.stats.govt.nz/surveys_and_methods/methods/classifications-
and-standards/classification-related-stats-standards/occupation.aspx 
• Phase of menopause: participants were asked about their stage of 
menopause. Some women were under chemotherapy treatment causing 
them to have irregular menstrual cycles and so their actual phase of 
menopause was confirmed from their medical notes.  
• Breastfeeding duration: women were asked how many children they 
had breastfed and for how long, then that time was added for all children 
together to calculate the total lifetime breastfeeding duration.  
• Body Mass Index (BMI): BMI for each patient was calculated using 
weight and height obtained from patients’ medical notes.  
• Chronic diseases: women were considered to have a chronic disease if 
they reported hypertension, diabetes, heart diseases, asthma and other 
diseases that require lifelong monitoring. 
• A family history of breast cancer: was defined as having a first-degree 
relative, i.e. sister, mother or daughter who had breast cancer.  
• Stage at diagnosis: T, N, and M categories of the tumours were 
recorded from patients’ medical notes. These were grouped to determine 
the breast cancer stage using the staging system of breast cancer 
published by the American Joint Committee on Cancer (Compton et al., 
2012).  
3.5 Data analysis 
The data was entered into an Excel spread sheet and the Statistical Package for 
the Social Science (SPSS) version 20 was used to analyse data. Frequencies of 
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the socio-demographic characteristics of the participants, their medical history 
and their clinical characteristics were calculated.  
To identify the most influential and important characteristics associated with 
patient delay, women in the two categories, no delay (< 3 month) and delayed 
(≥3 months), were compared using cross-tabulation analysis. The Chi-square 
test, or Fisher’s exact test (where there were cell counts less than 5) were used 
to assess the significance of the association between potential patient 
characteristics and patient delay. In all tests, p ≤ 0.05 was regarded statistically 
significant. 
Answers to the open questions that were used to enquire reasons for delay were 
categorised to different themes, some of which were similar to those identified 
from the literature review as qualitative analysis is beyond the scope of this 
research.  
3.6 Ethical considerations 
Ethical approval was obtained from the Ministry of Health in Oman in order to 
recruit participants from the RH. In addition, another approval was obtained 
from the SQUH Research Committee to include patients from the SQUH. 
Finally, as a student of the University of Otago, ethical approval was obtained 
from the University of Otago Human Ethics Committee. 
3.7 Results  
3.7.1 Study population 
The study sample consisted of 150 patients with 94 patients recruited from the 
RH and 56 patients recruited from SQUH. Four eligible patients declined to 
participate in the study. Table 3-1 shows the socio-demographic characteristics 
of participants. Their age ranged from 27 to 71 years with a mean of 46.3 years 
(SD 10.4). The majority (60.7%) of patients were < 50 years old, 35.3% 
between 50-65 and only 4% of patients were 65 years or over. The majority 
(75.3%) of the participants were married. Academically, 31.3% of the patients 
were illiterate, while 45.3% of patients had a high school or less education level 
and 23.3% had higher (university) education. 81.3% of participants resided in 
an urban city compared to 18.7% coming from rural places and the majority of 
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them had access to a near medical centre within 15 minutes or less (mean=10.8 
minutes SD 10.8).  




Age group   
27-34 years 25 16.7 
35-49 years 66 44.0 
50-64 years 53 35.3 
≥ 65 years 6 4.0 
Marital Status   
Married 113 75.3 
Never Married (single) 9 6.0 
Widowed 17 11.3 
Divorced 11 7.3 
Education level   
Illiterate 47 31.3 
Secondary school or less 39 26.0 
High school certificate 29 19.3 
Higher education (university) 35 23.3 
Place of residence   
Urban (large city) 60 40.0 
Urban (small city) 62 41.3 
Rural (Village) 28 18.7 
Travel time to nearest medical centre   
>15 130 86.7 
16-30 17 11.3 
31-60 2 1.3 
>60 1 0.7 
Occupation   
Retired 6 4.0 
Housewives 111 74.0 
Education professionals 15 10.0 
Health professional 5 3.3 
Marketing professional 2 1.3 
Personal service worker 1 .7 
Clerical and administrative worker 10 6.7 
Household income   
200-500 82 54.7 
600-900 38 25.3 
1000+ 30 20.0 
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Table 3-2 shows the medical history of the participants. 52% of patients were 
premenopausal with a mean age of 38.3 years (SD 5.6) and only 4 patients were 
going through menopause. Only 29 patients (19.3%) had a family history of 
breast cancer and 57 (38%) had co-morbid chronic disease. 45.3 % of patients 
were obese with BMI >30, 29.3% were overweight with BMI of 25-30 and 
25.3% had a BMI ≤ 25 with three patients being underweight.  
Table 3-2: Medical histories of the participants 
Medical history Frequency 
N=150 
% 
Phase of menopause   
Pre-menopause 78 52.0 
Going through menopause 4 2.7 
Postmenopausal 68 45.3 
 History of chronic disease   
No 93 62.0 
Yes 57 38.0 
 Family History of Breast Cancer   
No 121 80.7 
Yes 29 19.3 
 BMI   
≤25 38 25.3 
25.1-30 44 29.3 
>30 68 45.3 
The reproductive history of participants who have had children (N=136) is 
shown in Table 3-3. The majority of respondents (90.7%) had children. 70.6% 
of patients with children had more than three children. 61% of women with 
children had their first child at the age of 21 years or less and the mean age of 
patient at first pregnancy was 20.6 (SD 5.8). Just over two-thirds of patients 
who had children had breastfed for a total of 18-36 months, but few had 
breastfed for more than 36 months.  
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Table 3-3: Reproductive histories of participants who had children 
Reproductive history Frequency 
N=136 
% 
 Do you have any children?   
No 14 9.3 
Yes 136 90.7 
Age at first child birth    
≤ 15 years 26 19.1 
16-20 years 57 41.9 
21-25 years 25 18.4 
26-30 years 22 16.2 
>30 years 6 4.4 
Number of children    
1 12 8.8 
2-3 28 20.6 
>3 96 70.6 
Number of children who were breastfed    
0 3 2.2 
1 12 8.8 
2-3 26 19.1 
>3 95 69.9 
 Total life time breastfeeding duration   
0 months 3 2.2 
1-6 months 12 8.8 
7-17 months 26 19.1 
18-36 months 95 69.9 
>36 months 3 2.2 
Table 3-4 shows the clinical characteristics of the participants. A palpable breast 
lump was by far the most common symptom, being present in 78.7% of 
patients. These included 87 (58%) who noticed a lump alone and a further 31 
(20.7%) who noticed a lump in association with at least one other symptom. 
Nipple symptoms (without a breast lump) including nipple discharges, retracted 
nipple and change in appearance of the nipple were reported by seven patients. 
Other symptoms of the breast such as heavy breast, breast pain, change in breast 
skin and axillary lump were reported less frequently (12.7%). 
With regards to stage at presentation 44% of patients had early stage disease 
(stage I/stage II) compared to 56% of patients with late stage disease (stage 
III/stage IV). 
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Presenting symptoms   
      Breast lump only 87 58.0 
     Lump with others 31 20.7 
Breast lump AND pain 12 8.0 
Breast AND Axillary mass 5 3.3 
Breast lump AND nipple changes 6 4.0 
Breast lump AND change in breast size  1 0.7 
Breast lump AND change in breast skin 2 1.3 
Breast lump AND arm Or shoulder Or back pain 5 3.3 
     Nipple symptoms 7 4.7 
Nipple changes 2 1.3 
Nipple discharges 3 2.0 
Retracted nipple AND pain 1 0.7 
Nipple discharges AND pain 1 0.7 
       Others 19 12.7 
Breast pain 2 1.3 
Heavy breast 1 .7 
Change in breast size 2 1.3 
Change in breast skin 4 2.7 
Breast AND Axillary mass 5 3.3 
Heavy breast AND arm pain 1 0.7 
Others (abdominal pain, coughing, shoulder pain) 3 2.0 
Nothing noticed (symptoms discovered during mammography screening or 
general check-up) 
6 4.0 
Stage at presentation   
I 11 7.3 
IA 11 7.3 
  II 55 36.6 
IIA 23 15.3 
IIB 32 21.3 
  III 58 38.6 
IIIA 36 24.0 
IIIB 17 11.3 
IIIC 5 3.3 




3.7.2 Knowledge and attitude toward breast cancer  
Patients were presented with a list of possible breast cancer symptoms and were 
asked to select the relevant symptoms. Almost all patients agreed that breast or 
axillary mass is a symptom of breast cancer while 67.3% believed that breast 
pain could be a symptom. Only 56.0% of patients knew that nipple retraction is 
a sign of breast cancer (Table 3-5).  
When participants were asked about the prevalence of breast cancer, the 
majority of them (92.7%) said that it is the most common female cancer. 5.3% 
declared ignorance about breast cancer prevalence. 64.7% of patients believed 
that breast cancer is preventable and curable. With regards to potential ways of 
early detection of breast cancer, 84.0% of patients believed that BSE is a way of 
early detection, 92.7% believed clinical breast examination (CBE) can detect 
breast cancer early, 95.3% reported that mammography is an early detection 
method and 64.7% of patients said that blood test cannot be used for early 
detection. Almost four out of five participants identified mammography as the 
main way of diagnosis for breast cancer. 
3.7.3 Breast self-examination (BSE) 
Only 37 participants (24.7%) performed BSE before their diagnosis of breast 
cancer though the majority 137 (91.3%) declared importance of BSE. However, 
out of 113 (75.3%) patients who were not performing BSE before diagnosis, 71 
(62.8%) patients were aware with the technique of BSE. In fact, 41 out of 113 
started performing BSE after diagnosis. 
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Knowledge about symptoms   
Breast/axillary mass   
Yes 149 99.3 
No 1 0.7 
Breast pain   
Yes 101 67.3 
No 49 32.7 
Nipple retraction   
Yes 84 56.0 
No 66 44.0 
Declare ignorance “I don’t know’ 2 1.3 
Knowledge about prevalence   
Breast cancer is the most common female cancer 139 92.7 
Another cancer is the most common cancer 3 2.0 
Declare ignorance “I don’t know’ 8 5.3 
Attitude about prevention and treatment    
Breast cancer is preventable and curable 97 64.7 
Breast cancer is incurable and fatal 1 0.7 
Breast cancer is in one’s fate  52 34.7 
Knowledge about ways for early detection of breast cancer   
Breast self-examination    
Yes  126 84.0 
No 24 16.0 
Clinical breast examination   
Yes  139 92.7 
No  11 7.3 
Mammography   
Yes 143 95.3 
No  7 4.7 
Blood test   
Yes 53 35.3 
No 97 64.7 
Declare ignorance “I don’t know’ 1 0.7 
Knowledge about main way of diagnosis   
Breast self-examination 6 4.0 
Clinical breast examination 9 6.0 
Mammography 124 82.7 
Blood tests 2 1.3 
Others  9 6.0 
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Performing BSE before diagnosis   
Yes 37 24.7 
No 113 75.3 
Familiarity of BSE now for people not performing it already 
(n=113) 
  
Yes 71 62.8 
No 42 37.2 
Importance of BSE   
Not important  13 8.7 
Important 137 91.3 
Performing BSE now   
Yes  76 50.7 
No  74 49.3 
 
3.7.4 Extent of delay 
 In the analysis for patient delay, only 144 patients were included and the other 
six patients were excluded because they did not discover their symptoms; rather, 
they were first discovered by health professionals. Three patients were 
diagnosed after having a mammography in the Mobile Mammography Unit 
provided by National Association for Cancer Awareness (non-governmental 
organisation). All three patients had early stage diagnosis (two patients with 
stage IA and one with stage IIB). A further one patient was diagnosed after an 
admission for hip fracture and she was discovered to have a breast lump, which 
she did not notice before, and was diagnosed with breast cancer at stage I. The 
final two patients were diagnosis after having a general check-up including, 
imaging and CBE and diagnosed with breast cancer stage IA.  
The median time taken by women in this sample between discovering the breast 
symptoms and seeing a doctor was 14 days. 56.9% of patients had a medical 
consultation in less than a month after detecting symptoms; in fact 48.6% of 
patients had their first visit within a week. 33 patients of the 144 (22.9%) met 
the definition of delay. Of those with delay, 27.3% delayed consultation for 
more than a year after the onset of symptoms. The frequency distribution of 
patients according to the time between onset of symptoms and initial medical 
consultation is shown in table 3-6.  
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Table 3-6: Frequency distribution of patients presenting with breast cancer according to duration of 
patient delay 
Duration of patient 
delay (months) 
Frequency % 
< 1 82 56.9 
1-2 29 20.1 
3-5 8 5.6 
6-12 16 11.1 
13-24 3 2.1 
25-36 1 0.7 
37+ 5 3.5 
Total 144 100.0 
3.7.5 Influence of socio-demographic factors on delay 
Table 3-7 shows patient delay and socio-demographic factors, and the result of 
the chi squared test. Delay was significantly associated with age (p=0.004).  In 
general older women waited longer than younger women before seeking 
medical help. Educational level was also found to be significantly associated 
with delay (p= 0.047). Patient delay was 2.8 times more likely to be reported by 
illiterate women (32.6%) compared to women with higher education (11.8%). 
When looking at the influence of occupation on the magnitude of delay, results 
showed that women who were housewives (27.8%) waited longer than 
employed women (8.6%). Delay was not significantly associated with other 
socio-demographic factors including marital status (p =0.536), place of living 
(p=0.275), travel time to the nearest medical centre (p=0.294) and household 
income (p = 0.174).  
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Table 3-7: Patient delay in breast cancer patient by socio-demographic factors 
Variable 
Patient delay 
P < 3 months 
N=111 [n (% of raw)] 
≥ 3 months 
N=33 [n (% of raw)] 
Age group     
27-34 years  24 (100) 0 (0.0)  
35-49 years  48 (75.0) 16 (25.0) 
0.004 
50-64 years  36 (72.0) 14 (28.0) 
≥ 65 years  3 (50.0) 3 (50.0)  
Educational level     
Illiterate  31 (67.4) 15 (32.6) 
0.047 
Secondary school or less  26 (70.3) 11 (29.7) 
High school certificate  24 (88.9) 3 (11.1) 
Higher (university) education  30 (88.2) 4 (11.8) 
Marital status     
Married  88 (79.3) 23 (20.7) 
0.536 
Never Married (single)  6 (66.7) 3 (33.3) 
Widowed  10 (66.7) 5 (33.3) 
Divorced  7 (77.8) 2 (22.2) 
Place of residency     
Urban (large city)  47 (81.0) 11 (19.0) 
0.275 Urban (small city)  47 (78.3) 13 (21.7) 
Rural (Village)  17 (65.4) 9 (34.6) 
Travel time to nearest medical centre     
>15  97 (78.2) 27 (21.8) 
0.294 
16-30  12 (70.6) 5 (29.4) 
31-60  2 (100) 0 (0.0) 
>60  0 (0.0) 1 (100) 
Occupation     
Employed  33 (91.7) 3 (8.3) 
0.021 
Housewife  78 (72.2) 30 (27.8) 
Household income (OR)     
200-500  57 (73.1) 21 (26.9) 
0.174 600-900  27 (75.0) 9 (25.0) 
1000+  27 (90.0) 3 (10.0) 
3.7.6 Influence of health characteristics, medical presentation 
and health behaviours on delay 
Table 3-8 shows patient delay and health characteristics, medical presentation 
and health behaviours. No significant association was found between delay and 
family history of breast cancer (p=0.983).  In contrast, a history of chronic 
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disease showed a significant association with delay where patients with 
comorbid chronic disease presented later than those without chronic disease 
(p=0.012), with 33.9% of patients with chronic disease delaying presentation for 
≥ 3 months compared to 15.9% without a history of chronic disease. Whether or 
not the patients had children was not associated with delay (p=1.000). Similarly, 
no statistically significant association was found between delay and BMI, or the 
nature of presenting symptom, or stage of disease. 
There was no statistically significant association between delay and the patient’s 
attitude about prevention and the treatment of breast cancer. The majority in the 
delay and non-delay groups believed that breast cancer is preventable and 
curable. Likewise, factors like disclosing discovered symptoms and knowledge 
about the prevalence of breast cancer among females did not show an 
association with patient delay. 
3.7.7 BSE and patient delay 
Patient delay tended to be less common among women who reported 
performing BSE before diagnosis (p= 0.001). Almost all patients (32 patients) 
who delayed ≥ 3 months did not practise BSE. Also patient delay was observed 
to be less common among patients who acknowledged the importance of BSE 
but the association was not statistically significant (p =0.162). 
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Table 3-8: Patient delay by health characteristics, presenting symptoms and health behaviour 
Variable 
Patient delay 
P  < 3 months 
N=111 [n (%)] 
≥ 3 months 
N=33 [n (%)] 
Family history of breast cancer    
Yes 20 (76.9) 6 (23.1) 
0.983 
No 91 (77.1) 27 (22.9) 
History of chronic disease    
Yes 37 (66.1) 19 (33.9) 
0.012 
No 74 (84.1) 14 (15.9) 
BMI    
<25 28 (75.7) 9 (24.3) 
0.905 25.1-30 31 (75.6) 10 (24.4) 
>30 52 (78.8) 14 (21.2) 
Phase of menopause     
Premenopausal 65 (84.4) 12 (15.6) 
0.059 Going through menopause  2 (66.7) 1 (33.3) 
Postmenopausal  44 (68.8) 20 (31.3) 
Do you have any children?    
Yes 101 (77.1) 33 (22.9) 
1.000 
No 10 (76.9) 3 (23.1) 
Nature of presenting symptoms    
Breast lump (with or without other symptoms) 90 (76.9) 27 (23.1) 
0.924 
Symptoms other than a lump 21 (77.8) 6 (22.2) 
Stage at diagnosis    
Early stage disease (I/II) 48 (78.7) 13 (21.3) 
0.694 
Late stage disease (III/IV) 63 (75.9) 20 (24.1) 
Disclosed symptoms    
No 15 (75.0) 5 (25.0) 
0.811 
Yes 96 (77.4) 28 (22.6) 
Prevalence of breast cancer    
Breast cancer is the most common female cancer 103 (76.9) 31 (23.1) 
0.412 Another cancer is the most common cancer 1 (50.0) 1 (50.0) 
Declare ignorance “I don’t know’ 7 (87.5) 1 (12.5) 
Attitude about prevention and treatment     
Breast cancer is preventable and curable 76 (81.7) 17 (18.3) 
0.074 
Breast cancer is in one’s fate  35 (68.6) 16 (31.4) 
Performing BSE before diagnosis     
Yes 32 (97.0) 1 (3.0) 
0.001 
No 78 (70.3) 33 (29.7) 
Importance of BSE    
Not important 8 (61.5) 5 (38.5) 
0.162 
Important 103 (78.6) 28 (21.4) 
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3.7.8 Reasons for patient delay 
Patients who delayed their consultation for three months or more were asked to 
provide reasons for delaying. There were 33 patients with delay of ≥ 3 month 
and reasons are summarised in Table 3-9. Two themes emerged to explain 
patient delay, patient individual characteristics and socio-cultural context 
characteristics. With regard to patient individual characteristics, 7 out of 33 
patients thought that their symptoms were normal and would resolve by 
themselves, while six patients recognised their symptoms to be abnormal but 
never thought it might be cancer. The majority of patients who thought their 
symptoms were abnormal were breastfeeding at the time they discovered the 
lump and almost all of them interpreted it as plugged milk ducts. Four patients 
thought that their symptoms were not worrying because no other symptoms 
were present or the lump was painless. Not seeing oneself at risk was a major 
reason reported by four patients. Being afraid of cancer treatment and 
embarrassment from being examined by a doctor arose as a reason for delay for 
four of the patients. Two patients reported using alternative medicine before 
seeking medical help. Family and work commitments were the two main 




Table 3-9: Reported main reasons for patient delay ≥3 months 






Patient thought that 
her symptoms were 
normal 
• “I	  thought	  it	  is	  a	  normal	  thing	  and	  will	  go	  with	  
time	  and	  I	  didn't	  think	  it	  will	  be	  cancer…it	  started	  
to	  get	  bigger	  with	  time	  and	  then	  I	  told	  my	  
daughter	  about	  It”	  
• “I	  thought	  the	  lump	  is	  part	  of	  normal	  physiology	  
of	  breast	  that	  comes	  during	  menstrual	  cycle	  and	  I	  
never	  thought	  it	  could	  be	  cancer”	  
• “I	  didn't	  think	  of	  it	  as	  cancer	  and	  therefore	  
ignored	  it”	  
• “I	  thought	  it	  was	  normal	  and	  didn't	  put	  in	  mind	  
that	  it	  would	  be	  cancer”	  
• “I	  thought	  of	  it	  as	  a	  normal	  lump	  due	  to	  change	  in	  
hormonal	  cycle	  and	  will	  disappear	  by	  time”	  
7  
Patient thought that 
her symptom was 
abnormal but it was 
not cancer. 
• “I	  thought	  the	  lump	  was	  due	  to	  obstructed	  milk	  
ducts	  and	  will	  disappear	  with	  time	  but	  I	  noticed	  it	  
to	  become	  bigger	  and	  then	  I	  just	  went	  to	  the	  
hospital”	  
• “I	  was	  breastfeeding	  at	  that	  time	  and	  I	  thought	  it	  
was	  due	  to	  milk	  collection	  till	  I	  noticed	  it	  didn't	  
disappear	  and	  visited	  a	  doctor”	  
• “I	  heard	  that	  breast	  cancer	  patients	  usually	  have	  
discharges	  but	  the	  lump	  wasn't	  …	  and	  when	  it	  got	  
bigger	  I	  thought	  I	  should	  go	  to	  the	  hospital”	  
• “I	  thought	  it	  is	  an	  allergy	  and	  will	  go	  with	  time,	  




• “I	  had	  the	  lump	  for	  about	  15	  years	  [ago]	  and	  didn't	  
trigger	  my	  attention	  because	  it	  didn't	  have	  any	  
other	  symptoms	  or	  pain”	  
• “It	  was	  painless	  and	  so	  I	  thought	  it	  is	  nothing	  
serious”	  
• “Before	  7	  months	  I	  had	  pain	  but	  because	  there	  was	  
nothing	  visible	  in	  the	  breast	  I	  thought	  it	  might	  be	  
normal”	  
• “There	  was	  no	  pain	  associated	  with	  the	  lump	  so	  I	  




Did not see oneself at 
risk 
• “I	  didn't	  regard	  myself	  as	  being	  at	  risk	  and	  so	  I	  
ignored	  the	  symptoms”	  
• “I	  didn't	  regard	  myself	  as	  being	  at	  risk	  and	  so	  I	  
didn’t	  think	  of	  it	  as	  serious”	  
• “I	  didn't	  regard	  myself	  as	  being	  at	  risk	  and	  I	  never	  
linked	  the	  symptoms	  to	  be	  cancer”	  
	  
4  
Lack of knowledge 
“I	  didn’t	  know	  the	  signs	  of	  breast	  cancer	  and	  one	  day	  I	  
saw	  a	  poster	  in	  the	  clinic	  about	  signs	  of	  breast	  cancer	  
that	  triggered	  my	  attention	  and	  thought	  it	  might	  be	  
cancer	  and	  visited	  the	  doctor	  immediately”	  
2  
Fear of treatment 
(surgery and 
chemotherapy) 
• “I	  saw	  the	  experience	  of	  breast	  cancer	  and	  its	  
treatment	  on	  my	  friend	  and	  I	  was	  afraid	  of	  having	  
surgery	  and	  chemotherapy”	  
• “I	  was	  afraid	  that	  it	  is	  cancer	  and	  I	  will	  have	  to	  have	  
surgery”	  
2  





Patient	  used	  alternative	  medicine	  (likes	  herbs	  and	  






• “I	  was	  busy	  with	  the	  housework	  and	  I	  didn't	  think	  it	  
could	  be	  cancer”	  
• “I	  had	  children	  and	  no	  one	  to	  take	  care	  of	  them	  
while	  I	  am	  a	  way,	  so	  I	  had	  to	  travel	  to	  my	  family	  
place	  so	  I	  can	  leave	  the	  children	  there	  and	  go	  for	  
treatment”	  
• “My	  husband	  just	  passed	  away	  and	  I	  didn't	  care	  
about	  it	  at	  that	  time	  and	  I	  didn't	  want	  to	  bother	  my	  
children	  to	  take	  me	  to	  the	  hospital”	  
3  
Work commitments 
“I	  had	  lot	  of	  things	  going	  with	  my	  work	  at	  that	  time	  




3.8 Discussion  
Breast cancer is the most common cancer in Oman constituting 24.8% of total 
cancer. The incidence rate of breast cancer increased from 13.8 per 100,000 
women in 1999 to 25.5 per 100,000 women in 2011(Al Lawati et al., 2013).This 
study is the first in Oman to determine the extent of patient delay for women 
with self-discovered breast symptoms and to investigate the specific reasons 
influencing this delay time. In this section, the strengths and limitations of this 
cross-sectional study of women with breast cancer are discussed. Then the 
major findings are discussed and compared with other similar studies. 
Recommendations are made for future research and policy makers.  
3.8.1 Strengths and limitations  
A major strength of this study was the careful and detailed collection of 
information on patient delay using face-to-face interviews using standardized 
questionnaires with content from the existing literature on delayed presentation 
in breast cancer. All questionnaires were filled in by the same interviewer 
during a direct interview with the participants. In addition, patients’ clinical 
information was collected from the medical records with the help of the 
consultants who usually see these patients in the clinics. Further, the participants 
were recruited from the two major hospitals in Oman that provide breast cancer 
treatment.  
A number of limitations should be kept in mind when considering the findings 
of this study. One limitation is the possibility of recall error as an issue for some 
women who may have wrongly recalled the date of their first symptoms as well 
as their first visit to the clinician. We tried to minimize this by reminding the 
participants of events in the calendar such as school holidays, religious/national 
occasions and birth dates, to help them remember important dates relative to 
their medical history. In addition collecting information regarding data about the 
onset of symptoms and of first consultations is probably more reliable than 
asking the patients about length of delay. The problem of selection bias is 
another limitation due to that fact that participants were only those who finally 
saw a doctor and excluded those who did not present to doctor for symptom 
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evaluation and so magnitude of delay might be bigger in reality. Additionally, 
selection bias might be present due the fact that participants were included after 
the diagnosis of breast cancer was made and did not include the patients who 
have died before the study was conducted, nor does it include those who had 
stopped attending follow-up clinics. Nevertheless, if it is assumed that those 
who died early had advanced disease and had longer delay that would suggest 
that patient delay was under-estimated in this study. Although this study has 
developed initial information regarding the magnitude of delay and factors 
associated with delay, future studies could conduct more qualitative, in- depth 
analysis in order to obtain a deeper understanding of the problem and to provide 
additional data for designing breast health promotion strategies that are 
culturally sensitive in Oman.    
3.8.2 Patient delay in Omani women with breast cancer     
In Oman, women present with breast cancer at a younger age than their 
counterparts in the West. The mean age of 46.3 years at diagnosis in this study 
is a clear contrast to the older age at diagnosis (mean age of 63 years) in 
industrial western nations (Chouchane et al., 2013). However, it is relatively 
consistent with other developing countries including neighbouring Arab 
countries where the majority of patients are under 50 years (Najjar and Easson, 
2010). 60.7% of our sample is under 50 years of age, compared with data from 
other Arab countries such as KSA where 78% of patients diagnosed are under 
the age of 50 (Ezzat et al., 1999). 
The median time taken by women in this sample between discovering the 
symptoms and seeing a doctor was 14 days. This result is in line with other 
published studies on patient delay from developed countries such as in the UK 
(13 days) (Nosarti et al., 2000) Germany (16 days) (Arndt et al., 2002) and NZ 
(14 days) (Meechan et al., 2002). However, it is much shorter than those 
reported from developing countries including Malaysia (2 months) (Norsa'adah 
et al., 2011), Libya (4 months) (Ermiah et al., 2012b) and Egypt (5 weeks) 
(Abdel-Fattah et al., 1999).  
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Most estimates of patient delay use the definition proposed in 1935 by Pack and 
Gallo, a time period of three months or more from symptoms discovery to the 
initial seeking of diagnosis (Pack and Gallo, 1938). By this criterion, 22.9% of 
women in the current study report delayed presentation of breast cancer 
symptoms. The majority of women in this sample presented to health 
professionals within one month after they discovered the symptoms. These 
finding are comparable to a study conducted in Iran where 25% of patients 
delayed >3 months but it is higher than those reported in developed countries 
such as Germany (Arndt et al., 2002), Ireland (O'Mahony et al., 2013a), UK 
(Burgess et al., 1998) and NZ (Meechan et al., 2002) where they reported a 
range of 14-19%.  
3.8.3 Participants’ characteristics and patient delay 
In consideration of previous research, I investigated the role of socio-
demographic factors on patient delay. In the current study it was observed that 
patients’ characteristics associated with delay included older age, low 
educational level and employment status. The study demonstrates an association 
between age and patient delay where older women tend to present later 
compared to younger patients. According to the systematic review by Ramirez 
et al. (1999), there is strong evidence that advanced age is a predictor of patient 
delay. Similar findings come from another systematic reviews done in six 
studies from the Middle East (Alhurishi et al., 2011). Nevertheless, a few 
studies showed no association between age and patient delay (Montazeri et al., 
2003). 
Several explanations why patient delay is more often found among older women 
have been suggested (see section 2.4). They might attribute their symptoms to 
existing chronic conditions or to aging (Arndt et al., 2002) or Fail to identify 
breast cancer symptoms or have poor knowledge about breast cancer risk factors 
(Grunfeld et al., 2002, Bish et al., 2005). Other studies showed that older 
women held a negative attitude toward breast cancer treatment (Burgess et al., 
2006, Bish et al., 2005). This poor level of knowledge regarding breast cancer 
could potentially contribute to delaying seeking medical help for cancer 
symptoms among this group. It is also possible that effect of age on delay is 
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affected by level of education among older patients as it is likely that older 
Omani women are illiterate or have low educational level. Therefore, older 
women, in particular, may require further information regarding the potential 
seriousness of breast changes and recommendations for action if they identify 
some symptoms. Since older age is a risk factor for both developing breast 
cancer and subsequent delayed presentation, any intervention strategies should 
target older women in particular (Montazeri et al., 2003, Grunfeld et al., 2002).   
The annual report on cancer incidence published by the Omani National Cancer 
Registry in 2011 showed there were 14.3% of women with breast cancer aged ≥ 
65years, a percentage that is bigger than the percentage reported in this study 
(4.0%). This finding suggests that older women might be under-represented in 
this study and the observed magnitude of delay among older women may be 
bigger if all older patients with breast cancer were included. All of the older 
women presented at the follow-up clinics in both hospitals at the time of this 
study agreed to participate and so this leave the possibility that some older 
women do not attend the follow-up appointments after the diagnosis for various 
reasons. It might be that older patients have co-morbidities or were diagnosed at 
advanced stage so breast cancer treatment would not improve their prognosis. 
Or it could be that due to travel distances to these two main hospitals, older 
women might find this a barrier, and thus prefer to attend the follow-up 
appointments at other closer regional hospitals.  
Being less educated and being housewives are significant predictors of patient 
delay in this sample of women. Alhurishi et al. (2011) reported that there is 
strong evidence of an association between low educational level and longer 
delay, while Ramirez et al. (1999) has provided moderate evidence for this 
association where three studies comprising 11174 patients showed positive 
associations compared to two non-supportive studies including 351 patients. On 
the other hand, Alhurishi et al. (2011) provided strong evidence that 
employment status was not related to patient delay in four studies conducted in 
Egypt comprising 1170 patients and so did studies from Germany (Arndt et al., 
2002) and NZ (Meechan et al., 2002). Women in their traditional roles as 
housewives do not usually have time for themselves as they have to deal with 
household chores, children’s needs and outdoor activities (Harirchi et al., 2005).  
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This study has found that marital status was unrelated to patient delay. The 
association between marital status and patient delay remains unclear (see 
section 2.4). Women with chronic disease are more likely to delay seeking help 
after discovery of breast symptoms. This finding is in agreement with previous 
studies. It is suggested that those women may attribute their symptoms to co-
morbid conditions.  
Neither family history of breast cancer nor the nature of presenting symptoms is 
related to patient delay in the current study. It is argued that women with a first-
degree relative with breast cancer are less likely to present late (Montazeri et al., 
2003, Meechan et al., 2002) (Ali et al., 2008). This might be due to high breast 
cancer awareness, which makes them more susceptible to promptly seek help 
after symptom discovery (Harirchi et al., 2005). Similarly, the discovery of 
breast lumps has been shown to reduce patient delay (Burgess et al., 2001, 
Abdel-Fattah et al., 1999, Montazeri et al., 2003, Bish et al., 2005). It is 
proposed that those with non-lump symptoms are less likely to attribute their 
symptoms to definite causes, are less likely to consider breast cancer (Burgess et 
al., 1998) and are more likely to believe that their symptom is harmless and 
does not require action (Nosarti et al., 2000, Arndt et al., 2002). In my study, 
there was no difference in delay between those who discovered a lump and 
those who discovered non-lump symptoms. Breast lump was by far the most 
frequent discovered breast symptoms in this sample and these findings suggest 
that those women failed to recognise the significance of a breast lump.  Hence, 
Omani women need to be educated about the different types of breast cancer 
symptoms and be educated in symptom recognition as well as encouraged to 
seek medical advice if symptoms are ambiguous.  
3.8.4 Patient delay and breast self-examination 
Practice of BSE was associated with shorter delay in this study. This finding is 
in line with other published studies on BSE and patient delay (Rastad et al., 
2012, Abdel-Fattah et al., 2000, Stapleton et al., 2011) (see section 2.4). In NZ, 
for example, women who discover their symptoms during regular BSE had 
shorter delay (Meechan et al., 2002). BSE is still scarce and inconsistent among 
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Omani women, which is similar to the case in other Arab countries (see 
appendix 3 for screening practice in the Arab women) (Donnelly et al., 2013).  
The benefit of BSE is being debated across the literature as discussed previously 
(see section 2.4). Majority of studies have shown that BSE failed to detect 
cancer at earlier stages or improve survival (Muscat and Huncharek, 1991, 
Newcomb et al., 1991, Holmberg et al., 1997). BSE has been questioned in view 
of two randomized trials: one from Russia and the other from Shanghai. The 
Russian trial recruited 122,471 women aged 40-64 between 1985 and 1989 
(Semiglazov et al., 2003). After nine years of follow-up, there were more breast 
cancer deaths in the group performing BSE than in the control group but the 
results were not statistically significant. The Shanghai trial started in 1989 and 
follow 266,064 women aged 31 to 65 for 10 years (Thomas et al., 2002). 
Results showed no difference in breast cancer mortality between the control 
group and intervention group. The result of both trials discredited BSE as a 
screening tool and showed that it greatly increases the number of benign lumps 
detected. Correspondingly, the official position of health authorities like the US 
Preventive Services Task Force and the Canadian Task Force on Preventive 
Health Care to issue recommendations against teaching BSE (Corbex et al., 
2012).  
However, several points are worth clarifying regarding both the randomized 
trials. Smith et al. (2006) pointed out that the evidence of these trials does not 
mean that BSE instructions is ineffective and that it would not be effective in 
any setting. In both trials there was limited room for BSE screening to achieve 
mortality reduction since breast cancer awareness in the population was already 
high and clinical stage at diagnosis was relatively good (Abdalla et al., 2012, 
Corbex et al., 2012). In the Shanghai trial, for example, approximately half of 
the tumours among the control group were stage TI or better, suggesting the 
trial does not carry benefits in down-staging breast cancer cases in Shanghai 
compared to other populations. Some authors suggest that BSE examination 
could be beneficial in increasing awareness and decreasing tumour size and 
stage at diagnosis in countries where mean tumour size is above 3-4 cm and 
most women present with stage III and IV (Corbex et al., 2012, Shulman et al., 
2010). Since this is the case in Oman, Oman could consider educational 
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programmes to increase female awareness about BSE and encourage it to 
determine whether it leads to early detection of breast lumps.  
3.8.5 Stage at diagnosis and patient delay  
More than half of the sample (56%) was diagnosed with late stage disease (III 
and IV). This percentage is in line with previous reports from Oman (Al-
Moundhri et al., 2004, Al-Moundhri et al., 2011, Al-Moundhri et al., 2003). One 
possible explanation for the high proportion of advanced disease is that those 
women may delay longer after they have discovered a breast symptom. Most 
studies have found the longer the delay, the more likely the women is diagnosed 
in advanced stages (Abdel-Fattah et al., 1999, Arndt et al., 2002, Montazeri et 
al., 2003, Ermiah et al., 2012a). Surprisingly, however, this study found no 
association between delay and stage of disease. This finding suggests that in 
addition to patient delay, system or provider delay may play a role in advanced 
stage presentation among Omani women, an issue that merits further 
investigation.  
Early stage at diagnosis is a key determinant of breast cancer outcome, because 
earlier stage disease has lower cancer mortality and requires fewer resources to 
provide effective treatment (Anderson et al., 2008). There is an urgent need to 
adopt a screening program in Oman to downstage the symptomatic patients and 
to detect cancer in asymptomatic at-risk populations. Screening by 
mammography has been accepted as the gold standard for early detection of 
breast cancer (Corbex et al., 2012). Due to the low level of overall incidence in 
Oman and similar developing countries, the younger age of the target 
population (40s and 50s) and because the high rate of false positive 
mammographic results, especially among young women, some authors have 
suggested that combination of mammography and clinical breast examination 
(CBE), (implementation of CBE for younger women aged <45 years and 
mammography for women 45 years onward), would be more promising and cost 
effective (Corbex et al., 2012, Asadzadeh et al., 2011, Al-Foheidi et al., 2013).  
The results from the Egyptian and Taiwanese control programmes indicate that 
using a two- phase screening, starting with CBE and continuing with 
mammography in case of suspected findings, could increase the overall 
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effectiveness of the programme in countries with low to medium risk of breast 
cancer (Asadzadeh et al., 2011).  
CBE is considered a valid screening tool for breast cancer. The Canadian 
National Breast Screening Study carried a trial where women aged 50–59 years 
were randomized to receiving CBE or CBE plus mammography. The trial 
showed no difference in mortality between the two groups (Al-Foheidi et al., 
2013). Another study was conducted in Jakarta, Indonesia to compare the 
effectiveness of CBE screening with mammography in an unscreened 
population of 1,179 women (Kardinah et al., 2014). Of the fourteen breast 
cancers that were diagnosed, all but one were detected by both CBE and 
mammogram; in only one did an abnormal mammogram detect a cancer that 
CBE failed to uncover concluding that CBE is nearly as effective as 
mammography in detecting prevalent breast cancers.  Two other randomized 
trials designed to compare CBE with no screening in countries without 
screening mammography programs are still in progress (Kardinah et al., 2014). 
Thereupon, the training of healthcare providers in performing effective CBE is a 
key program component. Breast Health Global Initiative has recommended 
when initiating mammography screening, it should first target a selective group 
of high-risk women and gradually expand to involve the entire population 
(Anderson et al., 2008).  
Breast cancer will continue to increase “predictably” in Oman and developing 
countries in coming years due mainly to two reasons: increasing life expectancy 
and adoption of western life-style particularly decreased parity, delaying age of 
childbirth, shorter duration of lactation and dietary habits associated with earlier 
menarche, all of which associated with increased risk for postmenopausal breast 
cancer (Anderson et al., 2008, Shulman et al., 2010).  
Cancer prevention through risk factor modifications should be advertised. It is 
evident from this study that obesity is prevalent in Oman as there were 45.3 % 
of participants who were obese with BMI >30 and 29.3% were overweight with 
BMI of 25-30. Health behaviours including maintenance of ideal body weight, 
regular physical activity, and avoidance of prolonged use of exogenous 
hormone therapy can have an important impact on breast cancer risk (Shulman 
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et al., 2010). Besides, these health behaviours will reduce risk for other chronic 
diseases, so they may be of high interest for general public health (Anderson et 
al., 2008). 
3.8.6 Reasons for patient delay 
There were 33 patients who delayed visiting a medical consultant for three 
months or more. Several reasons for the delay were provided by those patients.  
Women falsely interpreted their initial symptoms as not cancer. Some women 
attributed their symptoms to be “normal” and tried to provide normal logical 
explanations for them. Initial interpretation of symptoms as “normal” is a 
frequent finding among participants from other studies (Unger-Saldana and 
Infante-Castaneda, 2011, Burgess et al., 2001, Arndt et al., 2002). Other women 
recognized that their symptoms were not normal but they were not of cancer. It 
has been demonstrated that women tend to attribute their symptoms to less 
serious conditions instead of life-threating disease (Bish et al., 2005) and that 
the interpretations of their symptoms to be ‘not serious’ is documented to be 
strongly associated with longer delay (Nosarti et al., 2000, Burgess et al., 2001). 
This was evident in this sample of women where they attributed their symptoms 
to allergies or plugged milk ducts or hormonal changes. It was also evident that 
those women monitored their symptoms and persistence of these symptoms led 
them to seek help. Continuous monitoring and reviewing of symptoms was also 
demonstrated in a study of British women (Burgess et al., 2001). 
 Persistence of breast cancer symptoms was one of the factors, which triggered 
help seeking amongst Mexican participants with self-discovered breast 
symptoms (Unger-Saldaña and Infante-Castañeda, 2011). Additionally, it has 
been shown that pain and visibility of symptoms trigger the seeking of medical 
help (Unger-Saldana and Infante-Castaneda, 2011).  In this sample, it was the 
absence of pain and non- visible symptoms, which was associated with delay. In 
a study from Egypt, women whose initial symptoms were not associated with 
pain, were 2.68 times more likely to delay compared with those who presented 
with pain (Stapleton et al., 2011). Symptoms appraisal to identify and label the 
initial symptoms is always the important first step in seeking medical evaluation 
(Bish et al., 2005). Ayers et al. (2007) stated that symptoms appraisal 
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constitutes approximately 60 % of total patient delay. Women will continue to 
apprise and decide whether a symptom means something is “wrong” and this 
doubt is the factor which will drive her decision to whether to seek medical 
evaluation. The way in which patients interpret and label their symptoms has 
been shown to influence help-seeking behaviour with a range of other illnesses 
like heart attack (Burgess et al., 2001). Norsa'adah et al. (2011) have stated that 
interpretation of initial breast symptoms is based on the pre-existing knowledge, 
experience, self-education and observation of individuals. If the woman has the 
knowledge regarding the variation of breast cancer symptoms, she will interpret 
the symptoms correctly and this will influence her assessment of symptoms as 
well her decision to seek medical attention. A study done on British women 
with breast cancer demonstrated that women who were likely to delay scored 
significantly lower on the breast cancer knowledge scale than women who are 
not likely to delay (Facione et al., 2002). 
Feeling safe from breast cancer and perceiving oneself as not being in the risk 
zone for breast cancer was another reason for delay in this sample. Perceived 
risk has an important role in determining and motivating one’s health behaviour 
and has been incorporated into many health behaviour models such as the 
‘health belief’ model (McQueen et al., 2008, Norman and Brain, 2005, Buxton 
et al., 2003). A willingness to undertake a health action after symptoms 
discovery is affected by woman’s perceived risk. One of many factors that 
influence perceived risk is the beliefs and knowledge about risk factors 
(Rothman et al., 1996). As discussed earlier in the literature review (see section 
2.3), findings indicate that women have a poor understanding and knowledge 
regarding breast cancer risk factors (Grunfeld et al., 2002, Williams et al., 
2002). Family history and its contribution to breast cancer risk was the most 
recognizable factor (Buxton et al., 2003, Grunfeld et al., 2002, Williams et al., 
2002). On the other hand, age, which is considered an important risk factor for 
breast cancer development, is poorly understood (McQueen et al., 2008, Vernon 
et al., 1993, Katapodi et al., 2004). Therefore, women with no experience or 
limited knowledge about breast cancer who perceive low risk of developing the 
disease are highly unlikely to undertake any early detection or awareness raising 
methods.  
 75 
Fear has been recognized as an important psychological factor in breast cancer 
delay across many studies (Rastad et al., 2012, Dubayova et al., 2010b, 
Stapleton et al., 2011, Norsa'adah et al., 2011). Fear is stimulated by many 
factors including symptoms of pain or discomfort, presumed diagnosis and 
anticipated consequences of treatment (Dubayova et al., 2010b). Fear usually 
provokes one of two opposite actions in the women that experienced it: either to 
delay or to prompt help seeking (Unger-Saldana and Infante-Castaneda, 2011). 
It seems women in this sample were provoked to delay as a result of fear from 
the therapeutic interventions of breast cancer as discussed earlier (see section 
2.4). Rastad et al. (2012) pointed out that fear is influenced by past experience 
of cancer in family or friends. Breast cancer treatment is believed to interfere 
with a woman’s ability to perform their role as a caregiver for their families and 
they have to rely on others to care for them (Norsa'adah et al., 2011). A sample 
of women from Jordan associated breast cancer with fear of distorted body 
image and loss of femininity, as it is affects a body organ that symbolizes 
femininity and motherhood (Taha et al., 2012). Fear from medical interventions 
for breast cancer has led some women to seek alternative therapy as a way to 
escape surgery. The use of alternative therapies could lead sometimes to 
worsening of symptoms and progressing to advanced stage of the disease 
(Ermiah et al., 2012b, Norsa'adah et al., 2011) 
Indeed, emotions such as fear are complex and multidimensional psychological 
factors which evidently influence the decision-making process in patient on help 
seeking behaviours (Dubayova et al., 2010a). Emotions and emotion regulatory 
styles differ systematically across nations and each culture has its own system 
of beliefs, perceptions, and ideas about health and illness which affect people's 
perception to illness (Iskandarsyah et al., 2014). Interaction between fear and 
perceived risk of breast cancer and their effect on patient delay is complex 
(Lipkus et al., 2000) and beyond the scope of this thesis. However, it is worth 
noting that fear is an important factor and should be taken into account when 
facilitating help seeking by patients.  It was observed that health education 
about cancer mostly tells people how to identify cancer symptoms but provides 
little about the consequences of a cancer diagnosis (Burgess et al., 2001). As 
Nosarti et al. (2000) pointed out "there is a delicate balance between scaring 
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women away from their doctors on the one hand (especially when they suspect 
the worst), and adding to a false sense of reassurance, thus taking away any 
motivation to come forward. Women should be encouraged to think of their 
breast symptom as ‘urgent but not necessarily serious’ and should be prompted 
to present to their doctor as soon as possible”. Therefore, information about 
clinical variables could be included in the content of health programmes for 
early help seeking (Dubayova et al., 2010a). Women should be informed of the 
benefits of early treatment on prognosis and that surgery is minimal if the 
cancer is diagnosed early enough.  
Embarrassment and shyness were another reasons for delay that were conveyed 
by only two participants in this study. They expressed feeling uncomfortable 
and shy about having their CBE done by a male doctor. In a sample 1002 Qatari 
women, 53.3% of them revealed that they were embarrassed by the performing 
of the CBE (Bener et al., 2009). A preference for female physicians in breast 
clinics was expressed by women from Egypt (Ismail, 2013), Jordan (Taha et al., 
2012), Saudi Arabia (Bener et al., 2001) and UAE (Bener et al., 2001). Ahmad 
et al. (2001) indicated that physician’s gender plays a role in sex sensitive 
examinations such as Pap test and CBE. This was reflected in male physicians 
reporting more frequent requests by female patients for another physician to do 
Pap tests and CBE. 
Further, there is evidence from this study that competing social demands in 
terms of family and work commitments acted as barriers to help seeking. Role 
demands such as devoting time and attention to the needs of someone else and 
taking time to make domestic arrangements prior to having biopsy may account 
for longer delay (Facione, 1993) (O'Mahony et al., 2011). Women’s 
prioritization of family and work demands over their own health has been 
recognized in many other studies. For example, a study from the UK identified 
practical issues (being too busy, having other things to worry about) as barriers 
to seek medical help for breast cancer examinations (O'Mahony et al., 2013b).  
After discussing the reasons for delay reported by women in this sample, it 
became clear that those women might have low awareness and knowledge about 
breast cancer. Particularly, they showed low knowledge regarding breast cancer 
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symptoms and signs, personal risk and risk factors, treatment modalities, and 
importance of early detection. Therefore, there is an urgent need to improve and 
raise level of awareness of breast cancer among Omani women. The Breast 
Health Global Initiative has emphasized that public education is the key first 
step in implementing breast health programmes (Anderson et al., 2008). 
Education should aim to raise women’s awareness of all potential breast cancer 
symptoms and encourage prompt help seeking for self-discovered breast 
symptoms. Such education programmes must convey the importance of early 
detection of cancer. In fact raising public education regarding early detection 
should be the first key step in implementing cancer prevention programmes 
because early detection programmes will not be successfully utilized if the 
public are unaware of the value of early detection (Yip et al., 2008).  
In addition, correcting the misconceptions around breast cancer treatment has to 
be included in educational campaigns. Women should be taught the scientific 
facts that early breast cancer can be treated and that mastectomy might not be 
necessary. It should be highlighted that the surgery may be minimal and there is 
the potential for breast conservation surgery.  There have also been advances in 
the management of side effects of chemotherapy (Burgess et al., 2001).  
Religious beliefs can influence how women think about cancer. Figures from 
this study indicate that 34.7% of our sample believes that breast cancer is one’s 
fate. This comes from the religious view of Muslim women that onset of illness 
is the will of God and it is not a matter of chance. This finding has also been 
documented in similar breast cancer studies (Taha et al., 2012, Lamyian et al., 
2007, Mitchell et al., 2002) (Cohen and Azaiza, 2008, Cohen, 2013), which 
have implications for the role of religious authority figures and for medical 
personnel in women’s decisions about breast health. Hence, collaboration is 
needed among medical professionals, policy makers, and religious leaders to 
persuade women that their religion can complement their (breast) health 
behaviour (Mitchell et al., 2002, Donnelly et al., 2013). Hatefnia et al. (2010) 
stated that religious leaders should communicate the fact that even though 
illness is the will of God, Islam also holds individuals responsible for their 
personal wellness, health and physical wellbeing, and “failing to take 
responsibility for one’s health is a serious sin”. So women should educate 
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themselves regarding breast cancer as well as participating in early detection 
programs. Equally healthcare practitioners should be aware of the role of 
religious belief in breast cancer help-seeking decisions and so they should enlist 
women’s religious beliefs as a supportive influence in women’s decision to 
pursue breast cancer preventive measures and treatment (Mitchell et al., 2002).  
 More attention needs to be paid to designing material for breast cancer 
awareness, in particular for women who are illiterate or less educated because 
this group would be reluctant to seek help if they were unaware of the meaning 
of breast mass and whether breast cancer is a curable disease or not (El-Shinawi 
et al., 2013). So the use of vivid images in health communication intervention 
should be incorporated through the use of narrative and visual illustrations (Yip 
et al., 2008). There is the suggestion that involving women living with breast 
cancer who would promote the perception that breast cancer is curable and “not 
a death sentence” could give women hope and encourage them to accept 
educational messages (Donnelly et al., 2013, Heisey et al., 2011). Furthermore, 
a woman help seeking behaviour is shown to be influenced by the social 
networks around her  (including family, friends, colleague at workplace) and the 
opinions of the significant other is often sought prior to seeking help from 
healthcare professionals (O'Mahony et al., 2011, Ayers et al., 2007). So it will 
be advantageous if appropriate health education programmes are directed at 
social support networks, which should encourage women to accept health 
education messages and enrol in early detection programs (Rastad et al., 2012, 
Yip et al., 2008).  
Public education and awareness about breast cancer is an important step towards 
improving breast cancer outcome. Mortality rates for breast cancer have been 
decreasing in the United States and many other western countries over the past 
25 years, due to improved treatment and early detection via mammography, 
which has been shown to increase treatment options and survival (Kardinah et 
al., 2014). Nevertheless, in the US and prior to the routine use of mammography 
or adjuvant therapy, which was commenced in the 1975, significant 
improvements were made in breast cancer survival. Between 1950 and 1975 
incidence nearly doubled but mortality remained constant (Shulman et al., 
2010). So during this period the ratio of mortality over incidence (an 
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approximation of the case-fatality rate) fell from 0.42 to 0.27 representing a 
36% decline, which suggests that more women were surviving their cancers in 
1975 as compared to 1950. This reduction in case-fatality rates is at least as 
large as the improvement evidenced since the introduction of mammography. 
Authors who analysed data prior to 1974 explain that the improvements seen in 
breast cancer survival result from more effective breast education programs, 
increased breast cancer awareness and detection of tumours palpable with self 
or clinical breast examination (Shulman et al., 2010). Similarly, in the UK, in 
the 1980s before the National Breast Screening Program began, the rate of 
advanced breast cancer fell dramatically and it is believed that this down-
staging was due to growing awareness that resulted from the greater presence of 
public education messages about early detection (Smith et al., 2006).  
Finally, a delivery of an organised and successful breast healthcare programme 
can be best accomplished if multiple sectors acted in collaboration (Anderson et 
al., 2008). Thus, improvement is most likely to be achieved when healthcare 
ministries and government organisations, national cancer institutes, education 
ministries and public and patients groups work together.  
3.8.7 Conclusion  
In conclusion, this is a cross-sectional study conducted to examine delay in 
seeking medical help for self-discovered breast cancer symptoms among a 
sample of Omani women. The median time taken by women in this study 
between discovering the symptoms and seeing a doctor was 14 days and 22.9% 
of women delayed for three months or more. Socio-demographic characteristics 
associated with patient’s delay included older age, low educational level, and 
being a housewife. Delay was not associated with marital status, or with 
household income. Neither it was associated with presenting symptoms nor with 
having a family history of breast cancer. Women who had chronic diseases 
seemed to wait longer. Although the majority of the sample was diagnosed at 
later stages (stage III and IV), there was no association between duration of 
delay and stage at diagnosis. Additionally, women who practised BSE presented 
earlier than those who did not practice it. Looking closely at reasons for delay 
reported by women who delayed for a month or more, it was evident that Omani 
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women have a low level of awareness regarding breast cancer including signs 
and symptoms, personal risk, available breast cancer treatment and the 
importance of early detection. Competing social demands in term of family and 
work commitment were also a reported reason for delay.  
To summarise the implication of this study:  programmes aiming to improve 
public health knowledge and awareness regarding breast cancer are needed in 
Oman. Efforts should be made to educate women about the variety of breast 
cancer symptoms and to prompt medical consultation for any changes noticed. 
There is a necessity for Omani women to be breast aware and to continually 
practice BSE and CBE. Training healthcare providers need to correctly carry 
out CBE and educating women on BSE is an important step in breast cancer 
controlling programmes. Additionally, educational campaigns must convey the 
idea that breast cancer is curable if detected earlier and that a mastectomy might 
not be required. The potential for breast conservative surgery must also be 
advocated. Educating the public to adapt a healthier lifestyle by increasing 
physical activity and paying more attention to diet and usage of external 
hormonal therapy might impact the incidence of breast cancer as well as other 
chronic diseases in Omani women. Importantly, more attention should be paid 
to raising the awareness of older women and those who are illiterate by 
designing materials that are easily understood and which might include images 
and illustrations. Finally, initiating a screening programme, possibly CBE for 
women aged < 45 years and mammography for women aged >45 years, should 
be considered in Oman to decrease late stage presentation of breast cancer and 
hence improve survival taking into consideration the WHO guidelines to assess 
the feasibility and appropriateness of such a programme (World Health 
Organization, 2002).  
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4 Chapter Four - Mortality and Survival of Omani 
Breast Cancer Patients  
4.1 Introduction 
The Omani National Cancer Registry (NCR) provides continuous information 
on the incidence of breast cancer among Omani women including frequency of 
cancer case, age-specific rates and morphology of cancer. Other data that the 
NCR routinely collects is all the information recorded on the Oman National 
Cancer Registry Form (see appendix 2). Information regarding mortality from 
breast cancer in Oman is still lacking which leaves a big gap in understanding 
the extent of its burden. The only mortality information available is aggregate 
hospital-based deaths, which are reported in the Omani cancer incidence reports 
(Figure 4-1). However, these are not representative of the whole population 
because many do not die in hospitals.   
 
Figure 4-1: Hospital-based breast cancer deaths 
Note:	  Figure	  generated	  by	  accumulating	  figures	  reported	  in	  the	  Omani	  cancer	  incidence	  reports	  
 
Up-to-date, studies on breast cancer survival among Omani patients are all 
hospital-based that are conducted to assess the outcome of cancer treatments in 
these hospitals [see (Al-Moundhri et al., 2004, Al-Moundhri et al., 2011, 
Burney et al., 2008)]. Results of theses studies are institution-based and not 
population-based which means they do not representative of the whole 
population beside patient who did not dies in hospital and were lost to follow up 
where censored. Therefore, there is a great need in Oman for population-based 
statistics concerning the mortality and survival cancer rates. These statistics 
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would provide information that is comparable with other populations and would 
uncover gaps in systemic policy and program delivery and help in planning 
cancer control systems.  
This chapter presents the research undertaken to provide data on survival rate 
among Omani women with breast cancer.  
4.2 Aim 
To calculate the population-based survival rate from breast cancer in Oman  
4.3 Methodology 
Cancer mortality is defined as the number of deaths occurring due to cancer, 
and the cancer mortality rate is the number of deaths due to cancer per 100,000 
persons per year in a defined population. Survival statistics describe the 
percentage of people with a certain type of cancer who will continue to live for 
a certain time after the cancer is detected. It was decided to calculate the 
population –based survival rates instead of mortality rates because the Omani 
NCR does not consistently record all cases of cancers and causes of deaths. 
There are two mortality databases in Oman which are the Directorate General of 
Civil Status (DGCS) located in the police IT network, which records deaths 
occurring outside the Ministry of Health (MOH) institutions (at home, in private 
health institutions or outside the country) and the Parallel Mortality Database 
(PMD) within the MOH which records deaths occurring in the MOH 
institutions. The DGCS lacks the capability to record all causes of death, and 
cause-of-death might be incomplete or inaccurate at the PMD. Therefore, it is 
not possible to calculate population-based mortality rates.   
The first stage in survival analysis is to define clearly the group of patients 
registered for whom calculations are to be made. Population-based cancer 
registries collect information on all cancer cases in defined areas. The survival 
rates for different cancers calculated from such data will therefore represent the 
average prognosis in the population. The Omani NCR is a population-based 
registry, which was established in 1996, although cancer notification did not 
become mandatory until 2001. Because the DGCS was only established by May 
2004 and because this study proposed to calculate 5-year survival rate, the 
linking was limited to patients diagnosed with breast cancer from 2005 to 2009. 
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Therefore, records of Omani breast cancer patients diagnosed from the 
beginning of 2005 to the end of December 2009 were sought.  
The second stage of calculating survival rates is to identify deaths among the 
group of women with breast cancer. Women with breast cancer who are 
registered on the NCR were sought in Oman’s mortality data to determine 
whether there is a record of their death. They were intended to be linked, firstly, 
to the DGCS (primarily to identify deaths outside MOH institutions) and, 
secondly, to the PMD (primarily to identify deaths in MOH institutions).  
The original plan was to follow a procedure developed by Al-Mahrouqi (2010) 
in his thesis “The Epidemiology of Stomach Cancer in Oman” which was to 
link records from NCR with records from the DGCS and PMD using specific 
identifiers to link cases. One identifier was the civil number, which is a unique 
number code given to every citizen in Oman. Al-Mahrouqi (2010) found that 
although the mortality databases (DGCS and PMD) in Oman recorded the civil 
number, the NCR did not record the civil number despite the fact that there is an 
allocated field for it in the Omani NCR form. This is because the civil number is 
missing in the medical records from which the cancer registry mainly obtains 
demographic information. Therefore, other personal details like full name, age, 
address had to be used to try to match information from the different data 
sources.  
4.4 Data collection and ethical approval  
A letter of support from the supervisors and a research proposal was submitted 
to the DGCS and they approved my obtaining data from their registry.  
To obtain the needed information there were several documents required which 
included a letter from University Supervisors in Oman and in New Zealand, 
confidentiality declaration and a study proposal. After these documents were 
provided and the research proposal was approved by the under-secretary of 
health affairs within the NCR, another ethical approval was required by 
Research and Ethical Review and Approve Committee within the MOH. An 
initial approval was given on 6th April 2014. However they required another 
proposal regarding obtaining raw data from the MOH. Final approval came on 
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9th July 2013 with a request to meet Director General of Planning and 
Chairman of the Ethical committee who explained to me that there were 
changes in the MOH policy regarding giving names of patients and names of 
diagnosed patients would not be made available.  
Consequently, without the names, an accurate linkage could not be carried out 
because address and dates of birth are insufficient for linkage with records of 
the PMD and DGCS. Therefore, the linking procedure was limited to those who 
had their civil number written down.  
4.5 Results  
I obtained addresses and date of birth for 547 patients from the NCR. However, 
only 93 patients had civil number. Only ten patients were identified to be dead 
through linkage with civil number and therefore survival analysis was not 
practicable for this small number. 
4.6 Discussion  
Policies and programmes to address health problems in a population require an 
understanding of the nature and extent of the problems, their causes and changes 
over time (Mathers et al., 2005). Equally, priorities for health research should be 
based on assessment of the relative importance of various diseases affecting the 
population of the health. The most commonly used data for meeting these needs 
and related needs for development of health policies includes incidence, 
mortality and survival (Parkin and Fernandez, 2006). Incidence data are 
annually reported by Omani NCR, but this study was aiming to provide 
population-based survival data for breast cancer in Oman. 
Mortality and information on deaths from cancer in any population is usually 
collected by civil registration system (recording vital events; birth, marriage, 
and deaths) (World Health Organization, 2002). Mortality data are normally 
derived from death certificates on which information about the death of the 
person and cause of death are certified, usually by a medical practitioner. Over 
the years, United Nations, WHO and International Institutes for Vital 
Registration and Statistics have intensified efforts to support the collection of 
vital information and mortality data (Sibai, 2004). The WHO stated that one of 
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its priorities is the strengthening of vital statistics registration systems (Mathers 
et al., 2005). It has developed the International statistical classification of 
diseases and related health problems (known as ICD) that provides a uniform 
system to codify cause of death allowing comparability between populations 
(World Health Organization, 2002). Almost all countries have legalisations that 
establish vital registration systems to collect and organise statistics on mortality. 
Nevertheless, for many countries of the world, vital statistics on cause of deaths 
are unavailable, cover very restricted population, are incomplete, or are 
inaccurate, especially if cause of deaths is certified by non-medical personnel 
(Mathers et al., 2005, Parkin, 2008). National-level mortality statistics are 
collected and made available online by the WHO which also provides tables of 
estimated coverage and completeness of data from different countries (Parkin 
and Fernandez, 2006). In Oman, the DGCS, a population-based registry, was 
established in 2004 as the body where all vital registrations (births, deaths, 
marriages, divorces) are recorded. However, the DGCS lacks the capability of 
documenting all deaths and cause-of-deaths. Consequently death notifications 
from the DGCS were sent to MOH where the PMD was established primary to 
record cause of deaths. It was noticed that also cause of death in the PMD was 
far from being accurate. Because cause of death was not documented in the 
DGCS and was inaccurate in the records of the PMD, the calculation of 
population-based mortality rate was not possible, given that it requires accurate 
and complete documentation of cause of death data.  
Many cancer registries aim to follow up their cases in order to produce survival 
statistics (World Health Organization, 2002). Many studies conduct survival 
analysis using population-based registry data and many population-based 
figures have been published (Parkin, 2008). For example, the Surveillance, 
Epidemiology and End Results program comprising 14 cancer registries 
covering 26% of US population and the EUOCARE project covering 12 
countries of Europe (Parkin, 2008). Unfortunately, the Omani NCR does not 
routinely collect data on the status of patients, so this study aimed to link the 
NCR records with the mortality database in Oman to assess the vital status of 
the breast cancer patients. Linkage was proposed to be done using different 
identifiers which includes civil number, and in case it was missing, the full 
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name, year of birth, address were to be used collectively to accurately identify 
cases. However, the documentation of civil number in the obtained records from 
the NCR was poor, and without the name of patients from the NCR, linkage 
between the records of NCR and mortality databases was not feasible.  
Cancer statistics are important in order to prioritize and allocate resources to 
combat the projected rise in cancer including the planning for cancer related 
health care (Parkin and Fernandez, 2006). Additionally, mortality data are 
widely used in evaluation and comparison of cancer rates between different 
populations and overtime to study differences in cancer risk (Parkin and 
Fernandez, 2006). Mortality statistics play a crucial role in demonstrating the 
effects which screening programmes have on burden of cancer. For example, a 
screening programme aimed at detection of pre-invasive cancer, as the case in 
breast cancer, reduction in mortality is the ultimate measure of its effectiveness 
(Jensen, 1991, Parkin, 2008). So it is important for any country planning a 
screening programme to have baseline mortality statistics prior to initiation of 
the programme, as well as to the continuing of monitoring mortality trends after 
that.  
Survival is one of the major outcome measurement and key criteria for 
assessing the quality of cancer control related to both prevention through early 
detection and therapeutic level (Seedhom and Kamal, 2011). Survival following 
a diagnosis of cancer is used to evaluate the impact of the extent to which new 
or improved cancer treatments are incorporated into clinical practice (World 
Health Organization, 2002). Such rates are also increasingly used to compare 
the effectiveness of cancer treatment in subsections of the country population or 
in different countries (World Health Organization, 2002). Survival rates vary 
greatly across countries due to different factors, such as difference in quality of 
cancer treatment facilities, in screening programmes, evidence-based best-
practice guidelines and in accessibility to new anti-cancer drugs (Verdecchia et 
al., 2007). Recognition of the differences in survival rates among population 
could assist the uncovering of failure in systemic policies and inappropriate 
programmes and further support the planning of system enhanced cancer control 
(Seedhom and Kamal, 2011, Parkin, 2008). The international comparisons of 
survival coordinated by the EUROCARE group, for example, have had a 
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profound influence in policy-making for cancer treatment services in several 
European countries.  
The improvement in the quality and completeness of mortality registration in 
Oman is essential for appreciating the burden of diseases and reforming health 
policies. Although survival and mortality analysis could not be carried out in 
this study, several recommendations for future references should be noted. 
Efforts to complete registration of patients’ civil numbers by the NCR are 
encouraged. Correct and complete recording of this number will facilitate fast 
and accurate linkage of NCR cases with the mortality databases to identify 
status of patients. Additionally, civil number will aid in NCR identifying 
duplicate entries from multiple primaries and also be helpful to be used by other 
bodies. Pharmacies, for example, could assess the effect of prescription drugs 
on the development or course of a disease (Al-Mahrouqi, 2010).  
An additional problem noted was the NCR’s lack of complete documentation of 
treatment and stage at diagnosis. Obtaining good quality data on cancer stages 
and treatment is urgently needed so that future studies examining survival 
differences could be explained in the light of prognostic factors, and for 
evaluating an appropriate cancer control programme such as breast cancer 
screening programme, where decrease in incidence of advanced stage reflects 
effectiveness of the programme. It is important to note that NCR primarily 
obtained their data from patients’ medical records, which are incomplete. 
Therefore, full documentation of NCR cases is dependent on completeness of 
medical records. Hence, accurate and full records of patient medical notes 
should be the goal among clinicians. Equally important is the availability of 
trained personnel to ensure that information about medical conditions leading to 
death is coded appropriately so the underlying cause of each death is easily 
identified. Moreover, The DGCS may need to make cause of death data 
available in their system to achieve a complete mortality registry where a single 
body contains all the relevant information. 
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5 Chapter Five - Conclusion 
Breast cancer is the most common cancer among women. In 2008, there were 
around 1.38 million new female breast cancer cases diagnosed worldwide 
(Ferlay et al., 2010). Breast cancer estimated to be responsible for around 
458,500 female deaths in 2008 or nearly one in seven (around 14%) of all 
cancer deaths in women (Ferley et al., 2010). In Oman too, breast cancer has 
been constantly topping the list every year. Age standardized incidence rate 
increased from 13.8 per 100,000 women in 1999 to 25.5 per 100,000 women in 
2011. In 2011, breast cancer accounted for 24.8% of all cancer diagnosed 
among Omani women (Al Lawati et al., 2013). Previous researches on breast 
cancer from Oman have found that majority of Omani females present with late 
stage of the disease (stage III and IV) (Al-Moundhri et al., 2004, Al-Moundhri 
et al., 2011, Burney et al., 2008). It is well documented that prognosis of breast 
cancer depends on stage at diagnosis and those diagnosed at earlier stage show a 
better survival rate (Kumar et al., 2007). Therefore, this project aimed to 
examine the epidemiology of breast cancer in Oman. This was done by 
conducting two small studies. The first study was aiming to explore the reasons 
for delaying seeking medical help for self-detected breast cancer symptoms in 
Omani women to help recommend solutions to shorten this delay. The second 
study was aiming to provide survival rate and mortality data from breast cancer 
in Oman.  
5.1 Main findings 
The median time taken by women in this study between discovering the 
symptoms and seeing a doctor was 14 days where 22.9% of women delayed for 
3 months or more. 
• Socio-demographic characteristics that was associated with patient’s 
delay included older age, low educational level, and being a housewife. 
Delay was not associated with marital status, and household income 
• Women who had a chronic disease seemed to wait longer. However, 
delay was not associated with family history of breast cancer, nature of 
presenting symptoms, and stage at diagnosis. Further, women who 
practised BSE presented earlier than those who did not practice it. 
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• From this study, it was evident that Omani women have low level of 
awareness regarding breast cancer in particular sign and symptoms, 
personal risk, available breast cancer treatment and the importance of 
early detection, all of which has been associated with longer patient 
delay. Competing social demand in term of family and work 
commitment was also reported as a reason for delay.  
• Due to incomplete documentation of civil number by the Omani NCR, 
and inability to obtain names of breast cancer patients from the NCR, 
linkage of NCR records to Omani mortality database was not possible.  
5.2 Implications 
Many of the implications of this project are relevant to health policy makers in 
Oman as cancer burden as general and breast cancer specifically will continue 
to rise in Oman and similar developing countries. The most important 
implications of this study are: 
• There is a need for educational programmes which aim to increase 
awareness and knowledge around breast cancer among Omani women. 
Educational campaigns should focus on educating women about various 
breast cancer systems, important to prompt medical attention for any 
changes noticed, and convey the idea that breast cancer is curable 
especially if discovered early. Omani women should also be taught to 
practice BSE and CBE and efforts should be made to train physician to 
appropriately carry CBE and encourage women to practice BSE. More 
attention should be paid to older and illiterate women, as those appear to 
be more likely to delay.  This could be done by designing materials that 
are easy to be understood, which might include images and illustrations. 
• Patient delay is associated with advanced stage at diagnosis. This study 
did not show an association between patient delay and stage of disease 
which suggest, in addition to patient delay, system or provider delay 
may play a role in advanced stage presentation among Omani women. 
Further studies to investigate provider delay and breast cancer is needed 
in Oman.  
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• Early stage at diagnosis is a key determinant of breast cancer outcome, 
because earlier stage disease has lower breast cancer mortality and 
requires fewer resources to provide effective treatment. Breast cancer 
screening is the best strategy to obtain this goal and screening by 
mammography has been accepted as the gold standard for early 
detection of breast cancer. Some authors have suggested that in countries 
like Oman, where the target population is young (40s and 50s), it might 
be more efficient and cost-effective to start screening by CBE for 
women aged <45 years and screening mammography for women aged 
>45 years. Nevertheless, WHO guidelines should be used to assess the 
feasibility and appropriateness of a population-based screening 
programme for breast cancer in Oman (World Health Organization, 
2002).   
• For the Omani National Cancer Registry, the quality and completion of 
cancer data collected must be encouraged. It will be important to follow-
up of patients registered at the cancer registry especially for survival 
studies. The availability of treatment and the status (dead or alive) of the 
patients are important for understanding the burden of cancer in Oman. 
Complete collection of civil number should be a priority for the NCR as 
complete documentation of it will l greatly facilitate regular collection of 
mortality data for cancer patients. Efforts should also be made to 
complete medical notes of cancer patients that will eventually be used to 
register them at the NCR. Oman should consider training personnel to 
ensure that information about medical condition leading to death is 
coded appropriately so the underlying cause of each death is easily 
identified.  
• The DGCS may need to make cause-of-death data available in their 
system to help in shaping a complete mortality registry where a single 
body contains all the relevant information. The improvement in the 
quality and completeness of mortality registration in Oman is essential 
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 Appendix 1: Questionnaire  
 
The Epidemiology of Breast Cancer in Oman 
Questionnaire 
a) Socio-demographic characteristics 
 
1. How old are you? ............................................... 
2. What is your educational level? 
o Illiterate 
o High school and less 
o High school certificate 
o Higher (university) education 
 
3. What is your occupation?  .......................................................... 
4. What is your family guardian’s occupation?  ................................................. 
5. What is your income and your total household income? ……………………..  
6. Where do you live? 
o Urban (large city) 
o Urban (small city) 
o Rural (village) 
7. How far are you from the nearest medical centre? What is your travel time 
in minutes?  
......................................................................................................................... 
b) Reproductive and Medical History 
1. Are you 
o Married  




Do you have any children? 
o No  
o Yes.         How many children do you have?   ....................................... 
 
2. How old were you when you had your first child? ....................................... 
3. How many of your children did you breast feed?  ………………………… 
4. How long in total have you spent breastfeeding (add time for all children 
together)?  ............................................(months/years) 
5. Are you 
o Premenopausal 
o Going through menopause at the moment 
o Postmenopausal    
6. What is your weight?  ............................... 
7. What is your height?  .................................. 
8. Do you have any history of chronic disease? 
o Yes – please specify: …………………… 
o No 
9. Do you have any family members with breast cancer? 




c) Symptoms and healthcare seeking behaviour 
 
1. When were you diagnosed with breast cancer?  (month /year)  
......................................... 
2. What was the stage of disease at the time of diagnosis?  
....................................... 
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3. What was the first symptom(s) you noticed? 
..............................................................................................................................
................................................................... 
4. Could you remember the date when you first noticed this symptom(s) 
(approximate month and year)?  
.................................................................................................. 
5. How many weeks was it between when you first noticed this symptom(s) and 
when you went to see a doctor?   
.............................................................................. 
6. Please remember back to how your breast cancer was diagnosed, which may 
have included X-rays and biopsy tests.  At the doctor’s appointment when this 
process first started, what was your reason for seeing the doctor?  (ie was it for 
the symptoms, and if so which symptoms, or for something else and the doctor 




7. If you waited for 3 months or more between first noticing breast symptoms 






8. Did you disclose the discovery of symptom(s) to someone else, before going 
to the doctor? 









d) Knowledge and attitude toward breast cancer  
 
1. What symptoms do you know of that breast cancer can cause?  (tick all 
mentioned) 
o Breast or axillary mass 
o Breast pain 
o Nipple retraction (‘pulled in’ nipple) 
o Other symptoms: specify: …………………………………. 
o 'I don't know' 
2. How common would you say breast cancer is compared with other cancers for 
Omani women? 
o Breast cancer is the most common female cancer 
o Another cancer is the most common cancer 
o  ' I don't know' 
 
3. Are you aware of any ways that breast cancer can be found in its early stages? 
o Self-examination 
o Doctor's examination 
o Mammography 
o Blood test 
o ' I don't know' 
o Other (specify): ………………………………………….. 
 
4. What is the main way of diagnosing breast cancer? 
o Self-examination 
o Doctor's examination 
o Mammography 
o Blood test 
o ' I don't know' 




5. Do you believe that : 
o Breast cancer is preventable and curable  
o Breast cancer is incurable and fatal  
o Breast cancer is in one's fate  
o Don’t know 
 
6. Before you were diagnosed with breast cancer, had you ever done Breast Self 
Examination? 
o Yes – how often? …………………… 
o No 




8. How important would you say Breast Self-Examination is? 
o Important 
o Not important 
 
9. Do you regularly perform Breast Self-Examination? 
o Yes specify how often: ……………………… 
o No 
 
That is the end of my questions. Thank you very much for answering them, and 
being part of this research project. Please keep the information sheet in case 
you have any questions about this project in the future. 
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Appendix 3: Arab Women’s Breast Cancer Screening Practices 
In most Arab countries breast cancer patients present with late stage disease and 
therefore survival rates are reported to be low among these patients (Donnelly et 
al., 2011b). Late diagnosis of breast cancer is shown to have an impact on the 
individual, society and government’s health resource expenditure (Ismail et al., 
2013). Early detection of breast cancer cases is linked to reduce morbidity and 
mortality. For example, mammography screening reduces mortality by 25% in 
women aged 40-74 years (Ismail et al., 2013). Consequently, decreasing 
incidence and mortality associated with breast cancer can be achieved through 
implementing early detection programs. Because of the lack of population-
based screening programs in the majority of Arab countries, participation in 
Breast Cancer Screening (BCS) is reported to be low (Donnelly et al., 2013, 
Akhtar et al., 2010). In Saudi Arabia, a pilot-screening programme was 
organised and results showed that only 18% of the total population in the target 
area participated (Akhtar et al., 2010). This percentage was lower compared to 
similar conducted pilot programmes in Europe and also than the recommended 
international standard of more than 70% (Perry et al., 2008). Similarly in Qatar, 
Bener et al. (2009) reported that only 22.5% of 1200 Qatari women aged 30-55 
years have ever attended mammography, and only 2.9% practiced BSE and 
13.8% had CBE. Similarly low participation rates were reported in UAE (Bener 
et al., 2001), Egypt (Abdel-Fattah et al., 2000), Palestine (Azaiza et al., 2010) 
and Jordan (Petro-Nustus and Mikhail, 2002).  
Individual health behaviour is determined by social and cultural context. 
Likewise, women’s beliefs, knowledge and practice of BCS are influenced by 
social and cultural frameworks (Donnelly et al., 2011a). Accordingly, 
investigating barriers and facilitators that influence women participation in BCS 
is vital in order to implement effective intervention programmes that are 
culturally and socially appropriate.  
Across the literature several barriers and facilitators of BCS have been 
identified in Arab countries. Lack of knowledge and awareness about breast 
cancer, and especially the benefits of screening, has been found as a major 
barrier (Bener et al., 2002, Soskolne et al., 2007). Poor knowledge seems to be 
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associated with under-utilisation of screening in low-income, poorly educated 
minorities and the elderly (Bener et al., 2002). Women who were aware of 
breast cancer causes were more likely to seek prevention. Ismail et al (2013) 
reported in a study on Egyptian women that more than half of the participants 
lacked knowledge about BSE. 
Fear is a well-recognised psychological barrier to BCS (Donnelly et al., 2013, 
Lamyian et al., 2007). Fear is believed to be associated with negative attitudes 
toward prevention. Fear of breast cancer being detected has been related to 
underuse of screening activities (Lamyian et al., 2007, Bener et al., 2002). In 
Kuwait, women revealed that they did not want to know if they had breast 
cancer (Al-Qattan et al., 2008). Equally, others never practiced BSE because 
they feared finding a lump or other abnormalities. On the other hand, some 
women stated that early detection was important to provide assurance that they 
did not have cancer. Additionally, fear of pain from mammography and CBE 
were reported in several studies (Cohen, 2013, Bener et al., 2009). In UAE, 
about a third of 367 women surveyed thought that mammography was painful 
(Bener et al., 2001, Azaiza et al., 2010). Others feared that diagnosis of breast 
cancer would affect their family relationship and marriage prospects 
(Chouchane et al., 2013). In particular, some women held the belief that 
screening could lead to the diagnosis of breast cancer and that this would 
interfere with their traditional duties in taking care of their houses and children 
(Baron-Epel et al., 2004, Azaiza and Cohen, 2008).  In contrast, this has been 
recognised as a motivator for women to seek early detection because their 
family depended on their continued health (Lamyian et al., 2007). Moreover, 
competing priorities, insufficient time to attend screening centres and 
forgetfulness were identified as significant barriers (Lamyian et al., 2007, Al-
Qattan et al., 2008). Easy accessibility of breast screening services is a well-
recognised facilitating factor (Chouchane et al., 2013, Ismail et al., 2013, 
Lamyian et al., 2007). Another barrier to access screening services is lack of 
transportation (Azaiza et al., 2010, Ismail et al., 2013). In some countries, there 
is inadequate distribution of screening centres (Donnelly et al., 2013). In some 
Arab countries where women are not allowed to drive or travel without a male, 
they are dependent on a male family member for transporting them to breast 
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screening facilities (Donnelly et al., 2011a). Cost and availability of health 
insurance might act as hindrances to screening services (Petro-Nustas, 2001). 
Another major barrier identified across the literature is lack of healthcare 
providers’ involvement in educating and offering screening. In Yemen, 36.5% 
of physicians referred asymptomatic patients for mammography, 26.9% referred 
those with breast cancer family history and 24.7% referred everyone regardless 
of symptoms status (Al-Naggar et al., 2009). In the UAE, while 80% of women 
were willing to undergo CBE, only 33% were offered CBE by physicians 
(Bener et al., 2001). A recommendation from health care providers has been 
found to motivate women to practice screening activities. “The doctor told me 
that when you turned 40, you should have a mammography every year and I 
have been doing it ever since” (Lamyian et al., 2007). Equally, a 
recommendation from a family member or friend has a positive impact on 
women attitude toward screening (Soskolne et al., 2007, Lamyian et al., 2007).  
Embarrassment and shyness are other psychological barriers (Cohen, 2013, 
Donnelly et al., 2013). Bener et al (2009) interviewed 1,002 Qatari women and 
revealed that 53.3% of women were embarrassed from performing CBE. Arab 
women tended to refuse to be examined by doctors especially for sensitive 
feminine places due to embarrassment and the influence of culture (Ismail et al., 
2013). Also unavailability of female doctors is conveyed as a barrier to BCS in 
Saudi Arabia (Bener et al., 2001). 97% of 1367 surveyed Emirati women 
showed a preference for female physician (Bener et al., 2001). Israeli Arab 
women state that they were uncomfortable with male examination but it was not 
seriously to be considered a barrier (Azaiza and Cohen, 2008). They believed 
that Islam would support medical examination by male doctor if a female was 
not available. Religion is found to act as an enabler for screening because 
women believe that religion is encouraging them to take responsibility for their 
own health. One woman said, “We have responsibility for our bodies. We 
should go to the doctor because it is a divine responsibility based on the divine 
teaching that humans should act and only then the help of God will come” 
(Lamyian et al., 2007). In contrast, fatalism expressed by some women who 
believe that cancer is deadly and that only limited influence on the course of the 
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disease was possible has been associated with low participation in BCS 
(Donnelly et al., 2013, Donnelly et al., 2011a). 
Therefore, each Arab country is recommended to identify and measure the 
magnitude of barrier to screening before developing effective prevention 
strategies that are socially appropriate, socially accepted and address each 
population’s unique needs (Donnelly et al., 2013).  
